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Abstract 
Latent TGF-β binding proteins (LTBPs) are extracellular matrix (ECM) proteins, which 
are recognized for their functions in mediating the secretion, ECM targeting and activation 
of transforming growth factor (TGF)-β, a multifunctional cytokine, which has many 
diverse, even conflicting effects. TGF-β can inhibit the proliferation of normal epithelial 
cells, and act as a tumor suppressor but it can also induce the proliferation of fibroblasts, 
and depending on the context act as a tumor promoter facilitating cancer invasion and 
metastasis. Strictly controlled mechanisms are required to regulate TGF-β activation in 
order to maintain tissue homeostasis. The LTBP-mediated spatial localization of TGF-β 
within the ECM determines how cell surface proteins and other constituents of the ECM 
become into contact with the latent growth factor to finally activate it. Therefore, the 
characterization of the ECM contacts of LTBPs can provide valuable information on the 
surroundings where the activation of TGF-β occurs, and thus it was chosen as one of the 
aims of this study. Because the efficient secretion of TGF-β requires LTBPs, the 
mechanisms regulating their expression in tissues impact on TGF-β biology. Furthermore, 
elucidating the mechanisms of transcriptional control of LTBP genes is critical if one 
wishes to gain a fundamental understanding on their tissue-specific expression but also on 
functions of LTBPs beyond the TGF-β binding. Thus, the current study was conducted to 
determine the regulatory regions of LTBP-3 and -4 genes.  
In silico and functional promoter analysis techniques were employed to characterize 
LTBP-3 and -4 promoter regions. The evidence gathered in this study indicated that the N-
terminal variants of LTBP-4, LTBP-4S and -4L, are under control of two independent 
promoters, which is in line with their specific expression patterns in human tissues. 
According to these investigations all promoter regions studied here were TATAless, GC-
rich and contained several potential sites for the initiation of transcription. These 
characteristics place them among the so-called broad promoters, which direct the 
expression of most vertebrate genes. Furthermore, the core promoter regions of LTBP-3 
and -4 were found to be highly conserved between human and mouse species. DNA 
sequence analysis recognized putative binding sites for Sp1 and GATA transcription 
factors controlling the basal and tissue-specific expression of many ECM genes, 
respectively. It was observed that TGF-β induced LTBP-3 promoter activity in 
osteosarcoma cells, which was consistent with the requirement of LTBPs for efficient 
TGF-β secretion. The induction of LTBP-3 promoter activity by TGF-β was mediated by 
concurrent activation of Smad and Erk MAPK pathways, as indicatated by the mutational 
analysis of the Smad3/4 and AP-1 binding sites and by MAPK inhibitory treatments. 
The ECM binding properties of LTBP-4S were studied by chromatographical methods 
combined with different binding assays. To locate the ECM binding sites, recombinant 
constructs were designed spanning the entire LTBP-4S molecule. The experiments 
emphasized that LTBP-4S has heparin binding sites, which are not only important for its 
ECM association, but also relate it to cell adhesion. Furthermore, LTBP-4S was found to 
have fibronectin (FN) binding sites in its N-terminal domain, which were indispensable 
for its ECM targeting. An immunofluorescence analysis revealed that LTBP-4S/FN 
interaction is particularly important in immature ECM, whereas in more complex ECM, 
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LTBP-4S likely associates with other ECM proteins, such as fibrillins. In addition, it was 
observed that the differences detected between the N-terminal variants of LTBP-4 also 
encompass their secretion and ECM targeting. Interestingly, it was found that LTBP-4L 
forms a complex with TGF-β1 more readily than LTBP-4S. 
This study has provided fundamental information on the transcriptional regulation of 
LTBP-3 and -4 genes, which is required to further understand their functions in tissues and 
also in pathological conditions, such as human cancers which are associated with aberrant 
expression of LTBP genes. Furthermore, the findings of this study help to provide a 
comprehensive view on LTBP-4 mediated TGF-β activation, which is influenced by the 
ECM contacts characterized here.  
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1 Review of the literature 
1.1 Extracellular matrix (ECM) 
1.1.1 Functions of the ECM 
Extracellular matrix is a complex three-dimensional network of various macromolecules 
surrounding cells that have created it. It provides physical support to tissues and organs 
and its constituents finally determine the unique architecture of these entities (Tsang et al., 
2010). Beyond these supportive and structural roles, ECM contributes to a number of 
cellular functions including proliferation, differentiation, adhesion, migration and cell 
survival (Marastoni et al., 2008). Due to these various activities, it is evident that 
alterations in the structure of the ECM can have dramatic effects on tissue homeostasis 
and may promote disease progression, e.g. osteoarthritis, fibrosis and cancer. 
1.1.1.1 ECM regulates cell signaling pathways through adhesion receptors 
Attachment to the ECM is a prerequisite for normal cell growth and survival. If cells lose 
their contacts to ECM or adhere to an improperly folded ECM, a particular cell death 
pathway, anoikis, is triggered (Gilmore, 2005). In contrast tumor cells have lost their 
anchorage dependence, which allows them to survive and invade neighboring tissues. 
Integrins are the primary cell-surface receptors, which attach cells to the surrounding 
ECM (Danen and Yamada, 2001; Legate et al., 2009). However, these receptors not only 
mediate adhesion of cells to their environment but at the same time activate signaling 
pathways regulating cell migration and gene expression, which ultimately controls cell 
survival, proliferation and differentiation (Legate et al., 2009). Integrins are heterodimeric 
molecules composed of α and β subunits, which form 24 different combinations in 
mammals (Hynes, 2002; Humphries et al., 2006). The combination of subunits defines 
those ECM components to which the particular integrin can attach. For example, α5β1 
binds to the RGD sequence of fibronectin, whereas αvβ5 recognizes the same sequence on 
vitronectin (Barczyk et al., 2010).  
Integrins mediate bidirectional signaling: adhesion to the ECM induce intracellular 
changes, but intracellular events also trigger changes in the extracellular part. Talin and 
kindlins are intracellular activators of integrins which bind the cytoplasmic tail of β 
integrins. This contributes to conformational changes which enable integrins to bind ECM 
ligands during cell adhesion, migration, ECM assembly and remodeling (inside-out 
signaling) (Shattil et al., 2010). The binding of integrin to the ECM ligand can also induce 
a transition into an active conformation (outside-in signaling). A particularly strong 
interaction between integrin and its ligands is acquired through integrin clustering. 
Clustering can occur by multiple mechanisms, one of which is the binding of integrins 
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with multivalent ECM ligand. The intracellular pathways that are activated as a 
consequence of integrin clustering and the following recruitment of other signaling 
molecules and adaptor proteins to the cytoplasmic tails of integrins include ERK and JNK 
MAP kinase pathways stimulated by the Src/focal adhesion kinase (FAK) complex (Fig. 
1). The activation of Rho-family GTPases (RhoA, Rac and Cdc42) by FAK regulates local 
actin assembly (Mitra et al., 2005) affecting cell adhesion, migration and polarity. In 
addition, integrins activate PI-3K/Akt pathway, which promotes cell survival. Activated 
growth factor receptors can affect integrin signaling, for example by regulating the activity 
of the integrin-associated signaling molecules, such as FAK and Src (Legate et al., 2009). 
Integrins also physically interact with growth factor receptors resulting in increased 
growth factor signaling. For example, the vitronectin receptor, αvβ3 integrin forms a 
physical complex with insulin-like growth factor receptor, platelet-derived growth factor 
receptor and with vascular endothelial growth factor receptor-2 (Schneller et al., 1997; 
Soldi et al., 1999; Borges et al., 2000). The binding of α5β1 integrin to FN instead can 
modulate epidermal growth factor receptor mediated signaling (Moro et al., 1998; Soung 
et al., 2010). Many of the receptor tyrosine kinase/integrin interactions play a role during 
cancer progression (Soung et al., 2010). 
 
 
Figure 1. Downstream signaling pathways of integrin activation. Integrin-associated signaling 
proteins FAK, Src and PI3K mediate the activation of ERK and JNK MAPkinases, the Rho family 
of GTPases and Akt. These signaling pathways which can be modulated by growth factor 
signaling regulate cell proliferation and survival among others. Based on (Legate et al., 2009). 
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In parallel to the integrins, the components of the ECM utilize many other cell surface 
receptors to exert their effects on cell signaling pathways. Among these, the cell-surface 
heparan sulphate proteoglycans (HSPGs), especially the transmembrane syndecans, 
mediate cell-ECM interactions, which modulate downstream pathways controlling cell 
adhesion and migration. Syndecans 1-4 are expressed in virtually all vertebrate cells. They 
are comprised of a protein core with covalently associated heparan sulfate (HS) chains 
facing the extracellular compartment.  HS chains are able to bind a variety of molecules, 
like growth factors, enzymes, chemokines and ECM components (Xian et al., 2010) and 
nearly all ECM molecules contain binding sites for HS (Bishop et al., 2007). ECM 
proteins to which syndecans can bind include collagens type I, III and IV, fibronectin (FN) 
and vitronectin (Schmidt and Friedl, 2010). Ligand binding induces multimerization of 
syndecans, which is mediated by the highly conserved sequence motif in the 
transmembrane domain (Lambaerts et al., 2009). As a consequence of multimerization the 
valency of syndecans is increased, which enhances their interactions with the ECM 
ligands (Xian et al., 2010). 
The short cytoplasmic domain of syndecans contains two highly conserved regions 
surrounding a variable region, which is specific for each syndecan. The molecular 
interactions of the cytoplasmic variable region of syndecan-4 have been the best 
characterized (Fig. 2). This syndecan recruits phosphatidylinositol (4,5)-biphosphate 
(PtdIns(4,5)P2) and protein kinase Cα (PKCα), which leads to the activation of the 
enzyme. PKCα activation is essential for focal adhesion (FA) formation. In these cell 
attachment sites, syndecan-4 co-operates with integrin α5β1 during cell adhesion to 
fibronectin (Morgan et al., 2007). Synergistic function of syndecan-4 and α5β1 integrin 
also activates focal adhesion kinase (FAK), which regulates FA disassembly. Syndecan-4 
binding to FN and the following activation of PKCα leads to the activation of the Rho-
family GTPases, which are important cytoskeletal regulators (Streuli and Akhtar, 2009). 
Integrin α5β1 is involved in modulating these signaling cascades, which regulate 
membrane protrusions and reorganization of the actin cytoskeleton (Morgan et al., 2007). 
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Figure 2. Co-operation between syndecan-4 and α5β1 integrin during adhesion on FN. A) 
Syndecan-4 binds phosphatidylinositol-4,5-biphosphate and protein kinase Cα which leads to the 
recruitment of talin to the cytoplasmic tail of α5β1 integrin. This PKCα-mediated activation of 
α5β1 integrin contributes to FA formation and adhesion to FN. B) The Src family of kinases that 
are activated due to integrin engagement phosphorylate the cytoplasmic domain of syndecans. 
Syndecan-4 can also activate Src. Synergistic function of integrin α5β1 and syndecan-4 activates 
Src and FAK contributing to focal adhesion disassembly. Based on (Morgan et al., 2007).  
In addition to syndecan-4, functional co-operation with integrins is observed in other 
syndecan-ECM interactions as well. It is known that syndecan-1 functions together with 
αvβ3 and αvβ5 integrins during adhesion to vitronectin and FN (Beauvais et al., 2004; 
McQuade et al., 2006), whereas α2β1 and α6β4 integrins collaborate with syndecans during 
adhesion to laminin (Hozumi et al., 2006; Ogawa et al., 2007). Additionally, α2β1 integrin 
supports syndecan-1 adhesion to collagen (Vuoriluoto et al., 2008). In vivo functions, in 
which both syndecans and integrins are involved and consequently are likely to co-
operate, include wound healing and angiogenesis (Morgan et al., 2007). However, it is 
likely that the integrin-syndecan interactions are more complicated in vivo and potentially 
involve other receptor interactions as well. 
Adhesion receptors like integrins and syndecans not only mediate information from the 
ECM into the cell but are equally important as organizers of the ECM. In particular, the 
role of integrins in FN fibrillogenesis has been thoroughly documented (Pankov et al., 
2000). Through interactions with integrins syndecans are likely to modulate ECM 
assembly. Moreover, several studies have indicated that, together with integrins, 
syndecan-1 remodels ECM structures by regulating the expression of matrix 
metalloproteinases (MMPs) (Gama-de-Souza et al., 2008; Vuoriluoto et al., 2008; Oh et 
al., 2009). 
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1.1.1.2 ECM determines the mechano-physical properties of tissues 
In addition to serving as a structural framework for cell adhesion and migration, another 
primary role of the ECM is to provide tissues with mechanical and physical support to 
allow them to maintain their structure. The structure of a tissue or organ is critical for its 
function and the loss of this organization contributes to disease progression. The structure 
and composition of the ECM varies depending on the tissue. Connective tissue is one of 
the four main tissue types and is characterized by the abundance of ECM components. 
However, ECM is present in every tissue to some extent. Basement membrane (BM) 
which is a specialized form of ECM provides structural support for cells of epithelial and 
endothelial origin. Collagens are the prevalent constituents of the ECM (see section 
1.1.2.1.1). In tissues, they form supramolecular assemblies like fibrils and non-fibrillar 
networks. The triple helical structure of collagens contributes to physical properties, which 
allow tissues to resist tensile and compressive forces. The density and distribution of 
different collagen structures in tissues is dependent on tissue type and on the magnitude 
and direction of the force to which the tissue is subjected (Rozario and Desimone, 2009). 
The fibrillar collagens, which include collagen type I, III and V provide tissues like tendon 
and bone with their structural strength. They are also responsible for the strength and 
resilience of the dermis (Tsang et al., 2010). In the cartilage, the biomechanical strength is 
obtained by the type II and type XI fibrillar collagen which associate with the type IX 
collagen. Type IV collagens, the constituents of the basement membranes, are required for 
the stability and integrity of the BM, starting in the early embryonic development (Pöschl 
et al., 2004). 
Elastins comprise another major group of ECM proteins (see section 1.1.2.1.2). In 
association with fibrillin microfibrils, they form elastic fibers which confer elastic recoil 
and resilience to connective tissues in organs under repeated stretching, such as the large 
arteries, lung and skin (Wagenseil and Mecham, 2007). The precursor molecule, 
tropoelastin is self-assembled on the cell surface. The packages of tropoelastin are 
crosslinked and then released to the extracellular space, where they are finally 
incorporated into maturing elastic fibers by microfibril-directed assembly (Wise and 
Weiss, 2009) (see section 1.1.2.1.2). Elastogenesis occurs mainly during early 
development, whereas adult tissues cannot assemble elastin properly (Wagenseil and 
Mecham, 2007). Although elastic fibers are progressively degraded during the course of 
life, leading to the loss of their original mechanical properties, they are considered to be 
highly stable polymers. 
Microfibrils which form a structural scaffold for tropoelastin aggregates are 
filamentous assemblies mainly composed of fibrillins -1 and -2 (Ramirez et al., 2008). 
Microfibrils can also form macroaggregates devoid of elastin. In tissues microfibrils and 
elastic fibers are organized in a manner to fulfill the mechanical demands of a particular 
organ system. Fibrillin-1 expression starts in the early development and continues to adult 
life when it is the main fibrillin isoform of connective tissues. The expression of fibrillin-2 
and -3 is limited to fetal development. In postnatal microfibrils fibrillin-2 forms the inner 
core which is covered by fibrillin-1 (Charbonneau et al., 2010). A number of mutations 
identified in fibrillin genes cause disorders which emphasize the importance of 
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microfibrils to connective tissue. FBN1 mutations cause Marfan syndrome (MFS) in 
humans affecting mainly the ocular, skeletal and cardiovascular systems (Dietz et al., 
1991). Increased TGF-β activation due to defective microfibril structure contributes to the 
pathogenesis in MFS (Neptune et al., 2003). In a mouse model of MFS, losartan which 
antagonizes TGF-β function prevented the progression of aortic aneurysm, which can 
contribute to life-treathening complications in MFS (Habashi et al., 2006). FBN2 
mutations cause congenital contractural arachnodactyly (CCA) with musculoskeletal 
manifestations which are likely caused by defective core structure of microfibrils 
(Charbonneau et al., 2010). 
The collagen scaffold of the ECM is surrounded not only by elastins, but there are also 
a number of different macromolecules present. These molecules are categorized into 
proteoglycans (PGs) and adhesive glycoproteins. The core protein of the PG is covalently 
associated to glycosaminoglycan (GAG) side chains, which are sulfated oligosaccharides 
composed of repeating disaccharide units of a hexosamine and a uronic acid. GAGs are 
polyanionic molecules which attract Na+ ions and water molecules. Therefore, in addition 
to their many other functions, PGs are indispensable for the osmotic properties and 
hydration of the ECM (Rozario and Desimone, 2009). A resulting amorphous, gel-like 
material fills spaces between ECM constituents and provides them with structural support. 
At the same time, it allows diffusion of nutrients and metabolites. Hyalectans are 
extracellular PGs, which aggregate with hyaluronan, a non-sulfated GAG polymer (Iozzo, 
1998). Versican and aggregan, which belong to the hyalectan PGs, play an important role 
in the organization of the ECM. Aggrecan resists compressive and shear forces in articular 
cartilage and, in addition to versican, is also present in tensile tendons (Rees et al., 2009). 
Versican interacts with a number of ECM molecules and is crucial for ECM assembly and 
remodeling. Perlecan is a secreted HSPG, which is incorporated into the BM to ensure its 
integrity to withstand mechanical force. It is also present as a pericellular PG in tissues 
devoid of BM, like articular cartilage (Melrose et al., 2006). Many of the HSPGs are 
involved in endochondral bone formation and homeostasis. Skeletal defects leading to 
perinatal lethality has been reported in mice with disrupted expression of perlecan and 
agrin (Rodgers et al., 2008). 
1.1.1.3 ECM serves as a repository for signaling molecules 
The constituents of the ECM possess various domains, which have the capacity to bind 
bioactive molecules like growth factors and cytokines. By harvesting these signaling 
molecules, the ECM thus regulates their distribution, and consequently activation and 
exposure to their receptors. HSPGs comprise the main group of molecules mediating 
growth factor/ECM interactions (Taipale and Keski-Oja, 1997). A classical example is the 
binding of fibroblast growth factor (FGF) to its receptor in the presence of 
heparin/heparan sulfate (Rapraeger et al., 1991; Yayon et al., 1991), which stabilizes the 
structure of the FGF/FGFR complex (Nugent and Edelman, 1992). In addition, the 
extracellular HSPGs bind growth factors like vascular endothelial growth factor (VEGF) 
(Gitay-Goren et al., 1992), hepatocyte growth factor (HGF)/scatter factor (SF) (Lyon et 
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al., 1994) and heparin binding epidermal growth factor (HB-EGF) (Higashiyama et al., 
1991; Higashiyama et al., 1993). These growth factors have been claimed to be important 
regulators of angiogenesis, wound healing and morphogenesis. Other PGs important for 
growth factor binding include biglycan, decorin and fibromodulin, which all bind TGF-β 
via their core proteins (Hildebrand et al., 1994). Growth factor binding PGs have been 
traditionally considered as coreceptors which only facilitate binding of growth factor to its 
cognate receptor. However, there is some evidence to indicate that PGs can directly signal 
via their transmembrane and cytoplasmic domains (Quarto and Amalric, 1994). In 
addition to PGs, ECM proteins bind growth factors and are important regulators of their 
activities. FN, a structural glycoprotein of the interstitial ECM, binds a number of growth 
factors such as TNF-α, HGF and VEGF (Alon et al., 1994; Rahman et al., 2005; Wijelath 
et al., 2006). Moreover, it can bind TGF-β in either an active form (Taipale and Keski-
Oja, 1997) or as a latent complex via fibrillins and/or LTBPs (Isogai et al., 2003; Dallas et 
al., 2005). Many of the growth factor/ECM interactions mediated by FN are crucial for 
normal development and wound healing. Collagens provide tissues not only with 
structural support but also with growth factor deposits. Platelet derived growth factor 
(PDGF) binds several collagen subtypes (Somasundaram and Schuppan, 1996). Active 
TGF-β has been proposed to associate with collagen type IV, a major constituent of the 
BM (Paralkar et al., 1991). In contrast, fibrillin-1 microfibrils bind the prodomains of bone 
morphogenetic proteins (BMPs), which are also members of the TGF-β superfamily 
(Sengle et al., 2008). 
Sequestering of signaling molecules to ECM enables prompt responsiveness to cellular 
needs without the requirement of new protein synthesis. Binding to ECM restricts the 
diffusion of bioactive molecules and depending on the localization (pericellular or 
interstitial) can lead to different outcomes. Growth factors in the close proximity to cells 
are more easily accessible for receptors, whereas those buried in the ECM may need more 
matrix remodeling either by enzymes or mechanical means before they become exposed. 
Therefore, the fibrillar components of the ECM are able to limit growth factor signaling. 
Signaling events initiated by ECM bound growth factors are confined to their vicinity. 
These growth factors may also provide more stable signaling, because the physical 
interaction with the ECM has been thought to prevent the endocytosis of the receptor 
complex (Taipale and Keski-Oja, 1997). In addition, the constituents of the ECM protect 
growth factors from degradation. 
ECM proteins contain functional domains which are capable of binding cell surface 
receptors of the cytokine, chemokine, ion channel, or growth factor receptor families 
(Tran et al., 2004). These matrikine subdomains such as EGF-like domains of tenascin-C 
and laminin are present as multiple repeats, which enhances the avidity of low affinity 
binding to their receptor. Binding of these ligands to the EGF receptor can upregulate cell 
migration during skin repair and tumor progression (Tran et al., 2005). Matrikines are 
either directly accessible as a part of ECM proteins (natural matrikines) or they first need 
to be exposed as a result of conformational change or proteolytic activity (cryptic 
matrikines). In order to mediate their unique effects on cell behavior, most of the natural 
matrikines bind to receptor tyrosine kinases, whereas cryptic matrikines utilize integrin 
receptors. Most of the effects that matrikines induce arise from their presentation, which is 
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constrained by the ECM molecule in question. The presentation of non-diffusible ligands 
like natural matrikines prevents ligand depletion by diffusion or receptor internalization, 
thus enhancing the effective concentration. Although some cryptic matrikines are 
proteolytically released from the ECM and are present as diffusible fragments, it does 
seem that they affect target cells in close proximity to their location. The majority of the 
cryptic matrikines are short peptide sequences for example derived from elastin (Duca et 
al., 2004), collagen type IV (Mundel and Kalluri, 2007) or collagen type XVIII 
(Wickström et al., 2005). Many of these are involved in progression, invasion and 
metastasis of cutaneous cancers (Tran et al., 2005). However, some cryptic matrikines 
contribute to different outcomes, depending on whether they exist as part of the ECM or as 
a soluble ligand. For example, the collagen derived matrikines arresten, canstatin, 
tumstatin and endostatin are inhibitors of angiogenesis, tumor growth and metastasis in 
their soluble forms (Mundel and Kalluri, 2007). 
1.1.2 Structural organization of the ECM 
Based on the morphological and functional properties of the ECM, two separate entities 
can be distinguished: the interstitial ECM and the basement membranes. Collagens are 
essential for stability of both these units, although their spatial organization and subtypes 
are different. Interstitial ECM contains fibrillar structures composed of various types of 
collagens, elastin and fibrillins, and one of their many roles is to maintain the structural 
strength and resilience of the ECM. Fibrillar structures of the interstitial ECM are 
surrounded by other ECM components like proteoglycans and adhesive glycoproteins. The 
most abundant proteoglycans of the interstitial ECM are the chondroitin sulfate and 
heparan sulfate containing subtypes, whereas the HSPGs, like perlecan, predominate in the 
BM. A number of different noncollagenous glycoproteins are important for the structural 
integrity of the interstitial ECM and the BM. Further, they provide recognition sites for 
cells and other ECM components as well. FN is an abundant glycoprotein found in the 
interstitial ECM, which is crucial for the assembly of various ECM molecules. It also 
interacts with cell surface receptors like integrins and syndecans and consequently plays 
an important role during development and tissue repair. In the BM, laminins are the 
predominant noncollagenous glycoproteins. In addition to these major structural 
components, there are many other associated molecules, which complete the functional 
structure of the ECM. 
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1.1.2.1 Interstitial ECM 
1.1.2.1.1 Collagen matrix 
There have been 29 family members of collagens characterized to date. These are the most 
prevalent proteins in the human body, accounting for one-third of the total protein mass. A 
vast number of mutations localized to collagen genes contribute to human diseases like a 
bone fragility disease, osteogenesis imperfecta, a blistering skin disease, epidermolysis 
bullosa, and a muscular dystrophy disease called Bethlem myopathy (Myllyharju and 
Kivirikko, 2004) and many others, thus demonstrating the importance of collagen 
proteins. Based on their structural features and assembly, collagens can be categorized into 
three main subgroups: fibrillar collagens, nonfibril-forming collagens and fibril-associated 
collagens with interrupted triple helices (FACIT) (Carter and Raggio, 2009). Fibrillar 
collagens (types I, II, III, V, XI, XXIV and XXVII) are the most abundant collagens, 
existing as fibrils in the ECM. Fibrillar collagens type I and V have a widespread 
expression pattern, whereas the others have a more restricted distribution in tissues and are 
mainly found in cartilage (collagen XXIV is present in bone and cornea) (Shoulders and 
Raines, 2009). In addition to cartilage, collagen types II and XI are the fibrillar collagens 
found in the vitreous humor (Tsang et al., 2010). Fibrils are not exclusively composed of 
one type of collagen, but contain minor amounts of other subtypes as well. For example, 
collagens type III, V, XII and XIV are found in the type I collagen fibrils, whereas types 
IX and XI are included in the type II collagen fibrils (Myllyharju and Kivirikko, 2004; 
Gordon and Hahn, 2010). FACIT collagens (types IX, XII, XIV, XVI, XIX, XX, XXI, 
XXII and XXVI) are non-fibrillar, but associate with the surface of existing collagen 
fibrils. A study on collagen type XIV has revealed that a reduced amount of FACITs on 
the surface of collagen fibrils likely contribute to increased interaction between separate 
fibrils further permitting the formation of larger fibrillar assemblies. In contrast, fibril 
fusions are prevented as a consequence of many bound FACITs present on the fibril 
surface (Ansorge et al., 2009). In addition to collagen type I and II fibrils, collagen type 
XII is known to associate with basement membrane components (Gordon and Hahn, 
2010). In addition, collagen types XVI, XIX, XXI and XXII are mainly present in 
basement membrane zones or junctions between tissues (Gordon and Hahn, 2010). A class 
of nonfibril-forming collagens is comprised of several subgroups: network-forming (types 
IV, VIII and X), transmembrane (types XIII, XVII, XXIII and XXV), anchoring fibril 
(type VII) and beaded microfibril collagens (type VI) together with multiplexins (multiple 
triple-helix domains with interruptions) (types XV and XVIII). This class also includes 
collagen types XXVIII and XXIX that contain von Willebrand factor domains (Carter and 
Raggio, 2009). 
Each collagen molecule is comprised of three polypeptide chains (α-chains), which 
intertwine around each other forming a triple helical structure in at least one region. 
Within the triple helical domain, the α-chains are comprised of repeating peptide triplets 
of glycine-X-Y, in which X and Y can be any amino acid, though most often proline and 
hydroxyproline, respectively (Myllyharju and Kivirikko, 2004). All α-chains can be 
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identical, but heterotrimeric triple helices are the more common (Shoulders and Raines, 
2009). Glycine enables the tight packing of the triple helix, since as a smallest amino acid, 
it is the only one that fits into the centre of the triple helix. The most severe mutations of 
collagen genes are single-base substitutions, which replace the glycine residue with 
another amino acid, preventing further folding or causing an interruption in the helix 
(Myllyharju and Kivirikko, 2001). Since the folding of the triple helices occurs from the 
C-terminus towards the N-terminus, the C-terminal glycine replacements tend to be more 
severe compared to their N-terminal counterparts. The role of proline and hydroxyproline 
residues is to provide stability to the helical structure. Characteristically, there is one 
interchain hydrogen bond per triplet codon contributing to this quality (Shoulders and 
Raines, 2009). Collagen prolyl 4-hydroxylase which catalyzes the hydroxylation of the 
proline residues is one of the key enzymes of the collagen biosynthetic pathway 
(Myllyharju, 2008). It is critically required for the formation of functional collagen triple 
helices at human body temperature. 
Outside the triple helical regions, all collagens possess non-collagenous (NC) domains, 
which also have important biological functions (see section 1.1.1.3.). Fibrillar collagens 
are synthesized as procollagen molecules having N- and C-terminal propeptide extensions, 
which are subsequently cleaved by specific procollagen proteinases during their secretion 
into the ECM. The C-terminal propeptides are important in initiating the association of the 
α-chains and providing solubility in the extracellular space, whereas the N-terminal 
propeptides influence fibril shape and diameter (Hulmes, 2002). In embryonic tissues the 
N-terminal propeptides are sometimes retained after secretion. For example, type IIA 
procollagen which is a splice variant expressed in chondrogenic mesenchyme and 
perichondrium is assembled into the ECM of precartilaginous mesenchyme, where it can 
bind regulators of chondrogenesis, like TGF-β1 and BMP-2, through its cysteine-rich N-
terminal prodomain (Zhu et al., 1999).   Following the cleavage of the N- and C-terminal 
propeptides in adult tissues collagen molecules assemble into fibers, a process which in 
vivo requires the presence of FN, integrins and minor collagens, like types V and XI 
(Kadler et al., 2008). Additionally, the small leucine-rich proteoglycans (SLRPs) decorin, 
biglycan, fibromodulin, lumican and keratocan regulate collagen fibrillogenesis (Iozzo, 
1999).The fibers are finally stabilized by covalent crosslinks which are formed as a 
consequence of oxidation of lysine and hydroxylysine residues by lysyl oxidase (LOX). 
Collagen molecules other than fibrillar collagens have also NC domains in their N- and C-
terminal regions, however, these are not cleaved during their processing (Myllyharju and 
Kivirikko, 2001). 
1.1.2.1.2 Elastin matrix 
The formation of elastic fibers is a complex process, which is affected by a multitude of 
proteins. Not all the details of the elastic fiber assembly have been characterized yet, but 
crucial contributors to this multistep process known so far are the cells, tropoelastin, lysyl 
oxidases, fibulins-4 and -5, LTBPs and microfibrils. The precursor molecule, tropoelastin, 
is secreted by vascular smooth muscle cells and fibroblasts. A single tropoelastin gene 
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gives rise to a protein, which depending on mRNA splicing, is approximately 60 kDa in 
size (Wise and Weiss, 2009). Tropoelastin consists of hydrophobic regions rich in glycine, 
valine and proline residues and hydrophilic regions with lysine and alanine residues. The 
latter amino acids are important for the stability and insolubility of the molecule, since 
they are modified by LOX enzymes to form covalent crosslinks like desmosine and 
isodesmosine. As a result of interactions between the hydrophobic domains of 
tropoelastin, a self-aggregation process called coacervation takes place, presumably on the 
cell surface. Tropoelastin is likely directed to the cell surface via glycosaminoglycans 
(Broekelmann et al., 2005). LOX enzymes crosslink the aggregates of tropoelastin, and it 
is believed that other proteins like fibulins, facilitate this process (McLaughlin et al., 
2006). Tropoelastin aggregates remain attached to the cell surface, which enables the 
association of new tropoelastin molecules and the formation of larger aggregates, which 
are finally released and directed onto microfibrils. Live imaging studies have indicated 
that cells actively participate in these events during elastic fiber assembly (Czirok et al., 
2006; Kozel et al., 2006). Once assembled onto microfibrils, tropoelastin aggregates are 
further crosslinked by LOX enzymes to form functional elastic fibers, which are crucial 
for the proper function of large arteries, lung and skin for example. 
1.1.2.1.3 Fibronectin matrix 
Within the ECM there are fibrillar structures which are constructed from noncollagenous 
proteins, like fibronectin. This insoluble multimeric form of FN is produced locally in 
tissues and then assembled into the ECM (cellular FN; cFN) in a cell-driven process. 
Another form is the soluble hepatocyte derived FN found in blood plasma (plasma FN; 
pFN), which is assembled into fibrils only after vascular injury. FN is secreted as a 
disulfide crosslinked dimer, which appears to be a requirement for ECM assembly to 
occur (Schwarzbauer, 1991). Both of its subunits contain repeating structural motifs 
termed type I, II and III modules and a variable region (V), which interact with cell 
surface receptors, other FN molecules and other components of the ECM. Altogether there 
are 12 type I, 2 type II and 15-17 type III modules (Magnusson and Mosher, 1998). A 
number of the type III modules depend upon alternative splicing for their formation, which 
also affects other parts of the molecule. As a result, a single FN gene can generate 20 
possible variants in humans (Pankov and Yamada, 2002). Mice lacking all FN isoforms 
die at embryonic day 8.5 due to defects in mesodermally derived tissues (George et al., 
1993). In addition to its role during early development, FN is involved in tissue repair 
processes. 
FN fibrillogenesis is initiated on the cell surface, where the dimeric molecule is 
directed primarily through interactions with integrin receptors (Mao and Schwarzbauer, 
2005). FN binds several integrins, of which α5β1 is the most important for FN fibril 
formation. The binding site of α5β1 integrin is an RGD (Arg-Gly-Asp) sequence residing 
within module III10 (Pierschbacher and Ruoslahti, 1984; Pytelä et al., 1985). The synergy 
sequence within the adjacent module III9 is also required for an efficient interaction 
(Nagai et al., 1991; Aota et al., 1994). The cytoplasmic tails of integrins connect FN to the 
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actin cytoskeleton, where the reorganizations take place. As a consequence, FN molecule 
is subjected to stretching, which reveals cryptic FN binding sites. The N-terminal 
assembly domain encompassing type I modules 1-5 mediates noncovalent FN-FN 
interactions, thus initiating fibril formation. The FN molecule also contains binding sites 
for many ECM components and thus organizes their ECM assembly. For example, 
trombospondin-1, collagen type I and III, LTBPs and fibrillins depend on FN in their 
ECM deposition (Sottile and Hocking, 2002; Velling et al., 2002; Dallas et al., 2005; 
Sabatier et al., 2009). 
1.1.2.2 Basement membrane 
Basement membranes, specialized extracellular matrices with sheet-like structures, play 
crucial roles during embryonic development and later in life in the creation of selective 
barriers and the structural scaffold. BMs underline epithelial and endothelial cell layers 
and separate them from stromal tissue. They also surround muscle cells, Schwann cells 
and adipocytes (Miner, 2008). In short, BMs are present wherever cells are in close 
proximity to connective tissue. In some special locations, BMs separate adjacent cell 
layers, like glomerular BM in kidney. The basic structural constituents of BMs are 
laminins, type IV collagens, nidogens and HSPG perlecan. Organization of these 
structural components is dependent on different isoforms expressed in a particular tissue 
type giving rise to variable functional properties. The BM zone, which integrates BM to 
connective tissue, contains agrin, fibulins, FN and various collagens (Aszódi et al., 2006). 
Animal models have indicated that mutations in certain collagen subtypes (collagen type 
VI, VII, XV, XVIII) lead to conditions associated with abnormal structure and function of 
muscles, skin and eyes (Bonaldo et al., 1998; Heinonen et al., 1999; Eklund et al., 2001; 
Fukai et al., 2002). These abnormalities partly occur as a consequence of improper 
anchoring of the BM to the underlining ECM. 
Laminins have been implicated as being crucial molecules in initiating the assembly of 
BM and at later stages of development and during adult life for providing stability and 
integrity to BMs. Laminins are heterotrimers composed of α, β and γ chains, which 
together form the 16 different isoforms identified to date (Colognato and Yurchenco, 
2000). The α chains contain a globular domain in their C-terminus, which is further 
subdivided into five laminin globular modules (LG) (Timpl et al., 2000). This region 
mediates interactions with cell surface receptors, like integrins, syndecans and 
dystroglycan, which direct the polymerization of laminins (Miner, 2008). Non-covalent 
intertrimer interactions between laminin N-terminal domains (domain VI) allow formation 
of a network-like structure, which supports contacts with other constituents of the BM. 
The early lethality of mouse embryos lacking the α1 (Miner et al., 2004), α5 (Miner et al., 
1998), β1 (Miner et al., 2004), or γ1 (Smyth et al., 1999) chain has demonstrated the 
crucial role of laminins in BM assembly during embryonic development. The vast 
numbers of other mutations in laminin genes give rise to severe human syndromes, further  
emphasizing the significance of laminins for the correct function of the BM (Schéele et al., 
2007). 
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Another network structure within the BM is composed of collagen type IV. Unlike 
laminin heterotrimers, collagen molecules form covalently crosslinked supramolecular 
structures. Six different genes encode the α chains (α1-α6) of collagen type IV, which 
assemble into heterotrimers in three different ways (α1α1α2, α3α4α5, α5α5α6) 
(Khoshnoodi et al., 2008). All tissues contain α1(IV) and α2(IV) chains, whereas the 
others have a more limited expression pattern. Moreover, the expression of the α chains 
varies temporally. Collagen IV heterotrimer contains cysteine and lysine residues in its N-
terminal region, which are important for crosslinking different heterotrimers with each 
other. The resulting tetramers (four heterotrimers) and dimers (two heterotrimers) formed 
via C-terminal interactions self-assemble to network-like structures, which are connected 
by lateral interactions (Yurchenco and Ruben, 1987). The collagen IV meshwork forms 
the structural scaffold of the BM, which is needed to guarantee its integrity under 
mechanical pressure (Pöschl et al., 2004). Various mutations in collagen IV genes have 
been identified, many of which affect kidney. In Alport’s syndrome, mutations prevent the 
developmental substitution of the embryonic α1α1α2 network in glomerular basement 
membrane by more resistant α3α4α5 network, contributing to renal dysfunction (Hudson 
et al., 2003). 
Like collagen type IV, HSPG perlecan is dispensable for the initial assembly of the 
BM, but is crucial for its structural integrity (Costell et al., 1999). The large number of 
structural modules of perlecan allows it to bind with many different growth factors and 
other constituents of the BM. In addition, nidogen glycoproteins, ubiquitously found in 
BMs, possess multiple binding sites through which they organize the BM structure. 
Nidogens are considered as crosslinkers between collagen type IV and laminin networks 
(Fox et al., 1991; McKee et al., 2007). 
1.1.3 Structural remodeling of the ECM 
ECM is a dynamic structure, which undergoes continuous remodeling (Daley et al., 2008). 
Cells can actively reorganize and degrade fibrillar structures in their surroundings. In 
particular, this occurs during embryonic development and tissue repair, but it is also 
associated with pathological conditions like cancer and arthritis. Several studies have 
revealed that ECM components undergo continual movements and deformations as a 
result of cell movements during morphogenesis. Time-lapse imaging of living osteoblast 
cultures has provided evidence that motile cells can assemble ‘packets’ of matrix material 
into existing fibrils and also mediate the exchange of fibrillar material between fibrils, 
which may represent a mechanism for ECM remodeling (Sivakumar et al., 2006). 
ECM density, composition and architecture are altered during ECM remodeling, which 
in turn affects cell behavior. The significance of ECM architecture has been demonstrated 
by studies which have revealed differences in cell characteristics in 2D versus 3D cultures 
(Cukierman et al., 2001; Yamada and Cukierman, 2007). Integrins are important 
mediators of signals contributing to ECM remodeling. Cytoplasmic binding proteins 
mediate the conformational activation of integrins and are also affected by other cell 
surface receptors, and thus their interactions with the ECM. Integrins act also as 
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mechanotransducers, which sense tension generated either by cytoskeletal elements or by 
the ECM. Cytoskeletal contraction is critical in initiating FN fibrillogenesis, whereas the 
contraction of collagen I matrix has been demonstrated to change survival signals to 
proapoptotic signals, at least in vitro (Tian et al., 2002). 
ECM degradation by proteolytic enzymes represents a significant way to remodel the 
structure of the ECM. Proteases belonging to the MMP, serine protease and cysteine 
protease families are tightly regulated, since they exert multiple effects on cells and their 
surroundings. Proteases can either directly degrade structural proteins of the ECM or 
affect cell behavior by releasing growth factors and signaling peptides from the ECM 
(Daley et al., 2008). Thus, malfunction of proteolytic pathways contributes to various 
diseases like cancer, in which upregulated proteolytic activity enhances ECM degradation 
and enables cancer cell invasion and metastasis. MMPs comprise a family of 23 
proteinases which degrade a number of substrates, including ECM proteins but also other 
proteinases and proteinase inhibitors (Cawston and Young, 2010). MMPs are considered 
as major ECM degrading enzymes and can be categorized according to their domain 
organization and substrate specificity into collagenases, gelatinases, stromelysins, 
matrilysins, membrane-type (MT)-MMPs and others (Nagase et al., 2006). Some MMPs 
are secreted as inactive proenzymes which are subsequently activated in a step-wise 
manner by other proteinases. MMPs with furin recognition sequence instead are activated 
intracellularly. Tissue inhibitors of metalloproteinases (TIMPs) can bind and inhibit 
MMPs. Thus, the ratio between active MMPs and TIMPs is critical for the extent of ECM 
degradation. 
1.2 Transforming growth factor β (TGF-β) 
1.2.1 Biological functions of TGF-β 
TGF-β was originally discovered due to its biological activity, which induced sarcoma 
virus transformed fibroblasts to grow in an anchorage independent manner (De Larco and 
Todaro, 1978). Subsequently was, however, recognized that TGF-β could act as a growth 
inhibitor to epithelial cells (Tucker et al., 1984), and this activity was extended to apply to 
endothelial, hematopoietic and immune cells as well. Three mammalian TGF-β isoforms 
(TGF-β1, -β2, -β3) constitute, together with other related proteins, the TGF-β superfamily 
with 33 members in humans (Moustakas and Heldin, 2009). The members of this family 
including TGF-βs, bone morphogenetic proteins (BMPs), growth and differentiation 
factors (GDFs), activins and nodal modulate embryonic development and maintain the 
tissue homeostasis in adult organisms. 
Cellular pathways affected by TGF-βs control cell proliferation, differentiation, 
adhesion, migration and apoptosis. In vitro, the biochemical activities of TGF-β isoforms 
appear indistinguishable. Despite their partially overlapping expression pattern, each TGF-
β isoform has specific functions in vivo, as indicated by gene knock-out studies. Mouse 
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models with targeted TGF-β1 mutation revealed that TGF-β1 was crucial for a functional 
immune system (Shull et al., 1992; Kulkarni et al., 1993). In two weeks, the TGF-β1(-/-) 
mice developed a multifocal inflammatory disease characterized by massive infiltration of 
lymphocytes and macrophages into multiple organs, but primarily into heart and lungs. 
Later studies have indicated that TGF-β exerts complex context-dependent effects on 
different T-cell subsets. Although TGF-β inhibits the proliferation, differentiation and 
activation of certain T-cells, it is indispensable for the development and maintenance of 
the other subtypes (Li et al., 2006). The TGF-β2 null mutation in mice causes a number of 
developmental defects affecting heart, lung, urogenital tract, eyes, ears and bones (Sanford 
et al., 1997). TGF-β2 deficient mice die perinatally, likely due to respiratory failure, 
because TGF-β2 is required for the correct synaptic function in the respiratory center of 
the brainstem (Heupel et al., 2008). TGF-β3 knock-out leads to abnormal lung and palate 
development in mice (Kaartinen et al., 1995; Proetzel et al., 1995), which, however, arise 
from distinct disturbed developmental processes than those causing the same defects in 
TGF-β2 null mice (Sanford et al., 1997). 
The growth inhibitory effects of TGF-β are mediated through induction of cell cycle 
inhibitors p15Ink4b, p21Cip1 and p57Kip2 (Hannon and Beach, 1994; Datto et al., 1995; 
Scandura et al., 2004) and through repression of c-Myc and Id family of transcription 
factors (Pietenpol et al., 1990; Kang et al., 2003). However, depending on the context and 
the cell type in question, TGF-β can also promote cell growth. In general, cells of a 
mesenchymal origin, like fibroblasts, proliferate in response to TGF-β, whereas cells with 
an endodermal origin are growth arrested.  Due to its antiproliferative effects together with 
its ability to induce apoptosis, TGF-β acts as a tumor suppressor. However, during 
progression of cancer, mutations in TGF-β pathway or on specific TGF-β target genes 
may allow cells to escape the growth inhibitory effects of TGF-β. On the other hand, 
tumor cells can benefit from TGF-β, which at later stages of cancer, functions as a tumor 
promoting factor, for example by inducing the expression of angiogenic factors (Padua 
and Massagué, 2009). Furthermore, the cellular pathways mediating the transcriptional 
activation of genes contributing to changes which promote the epithelial to mesenchymal 
transition (EMT) are under the control of TGF-β. During EMT, adherent cells acquire a 
fibroblast-like phenotype with an increased migratory capability. This transdifferentiation 
process is essential during embryonic development, but also enhances cancer progression, 
allowing tumor cells to invade and metastasize (Miyazono, 2009). The molecular 
mechanisms by which TGF-β induces EMT include the induction of the transcriptional 
repressors of the cell-cell adhesion receptor, E-cadherin (Snail, Slug, γEF1, SIP1), and 
disorganization of tight junctions through phosphorylation of the tight junction protein, 
Par6 (Miyazono, 2009). 
TGF-β also regulates the expression of various genes encoding ECM proteins, 
proteolytic enzymes and their inhibitors, which is fundamental for the proper function of 
tissues (Verrecchia and Mauviel, 2002). FN and various collagen genes are known targets 
of TGF-β (Verrecchia et al., 2001a). Furthermore, there are reports that the expression of 
protease inhibitors PAI-1 (plasminogen activator inhibitor) (Laiho et al., 1986) and TIMP-
1 (tissue inhibitor of metalloproteases) is upregulated by TGF-β (Verrecchia et al., 2001a), 
whereas the expression of many ECM degrading proteases, like MMP-1, is downregulated 
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in dermal fibroblasts (Yuan and Varga, 2001). The production and remodeling of the ECM 
occur during wound healing, being directed by TGF-β, which is derived from wound-
associated platelets, inflammatory cells and fibroblasts (Margadant and Sonnenberg, 
2010). TGF-β initiates the formation of granulation tissue by inducing the proliferation 
and differentiation of fibroblasts and by inducing fibroblasts to express ECM proteins. 
Furthermore, TGF-β upregulates integrin expression, which is critical for cell adhesion 
and migration, but it also regulates TGF-β signaling during wound healing (Margadant 
and Sonnenberg, 2010). In fibrotic diseases, the reaction to organ or tissue injury is 
persistent. It leads to the increased proliferation of fibroblasts followed by excessive 
production of ECM, which eventually prevents the normal function of the affected organ 
(Pohlers et al., 2009). 
1.2.2 Synthesis and secretion as a large latent complex 
TGF-βs are ubiquitously expressed proteins and nearly all cells have receptors for these 
growth factors. Bone and platelets are particularly rich sources of TGF-β. TGF-βs are 
synthesized as homodimeric proproteins, which are held together by three intermolecular 
disulfide bonds. These proproteins contain the N-terminal propeptide part called the 
latency associated peptide (LAP) and the mature TGF-β at the other end of the molecule 
(Lawrence et al., 1984; Gentry et al., 1988), which are cleaved apart by furin-like 
proteases, while in the secretory pathway (Dubois et al., 1995). The 75-80 kDa propeptide 
serves as a chaperone and remains attached to the dimeric growth factor of 25 kDa 
through noncovalent interactions (Gentry et al., 1988; Gentry and Nash, 1990). The 
structure of the resulting complex, referred to as the small latent TGF-β (SL-TGF-β or 
SLC), prevents the mature growth factor to access its signaling receptors. The secretion of  
SL-TGF-β is facilitated when it is bound to an LTBP-molecule (Miyazono et al., 1991). 
The formation of this complex, termed the large latent TGF-β (LL-TGF-β or LLC), occurs 
via disulfide bonding between the 3rd 8-cysteine repeat of an LTBP molecule and the N-
terminal cysteines of the LAP dimer (Saharinen and Keski-Oja, 2000). LLC is the 
predominant form, in which most non-transformed cells secrete TGF-β (Fig. 3). LTBPs 
deposit TGF-βs into the ECM, from where they are subsequently released and activated 
through mechanisms which appear to vary depending on the TGF-β and LTBP isoforms in 
question. LTBPs-1 and -3 are able to form complexes with all three TGF-β isoforms in 
vitro, whereas LTBP-4 associates only with TGF-β1 (Saharinen and Keski-Oja, 2000). 
Despite its name, LTBP-2 does not associate with any isoforms of TGF-β. This isoform 
specific binding fine-tunes the activation of TGF-β in tissues. In addition to canonical 
TGF-β family ligands, LTBP-3 can associate with promyostatin, a negative regulator of 
muscle growth, in cultured cells (Anderson et al., 2008). 
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Figure 3. Large latent TGF-β complex targeted into the ECM. The small latent TGF-β complex 
is disulfide-bonded to the 3rd 8-Cys repeat of LTBP. The resulting large latent TGF-β complex 
associates ECM through the N-terminal region of LTBP-molecule. Modified from (Saharinen et 
al., 1999). 
1.2.3 Activation of latent TGF-β 
In view of the fact that TGF-β has so many biological functions, it is evident that its 
activity has to be tightly controlled. Any aberrations in this balance may have disastrous 
consequences, as described for the development of cancer, autoimmune disorders, 
vascular and fibrotic diseases. It has become evident that ECM components can act as 
regulators of TGF-β bioavailability and TGF-β signaling. Compelling evidence has 
emerged from studies on the Marfan syndrome, an autosomal dominant disorder of 
connective tissues particularly affecting the skeletal, ocular and cardiovascular systems 
(Robinson et al., 2006), in which the defective ECM structure contributes to aberrant 
sequestration and consequently to excessive activation of TGF-β (Neptune et al., 2003). In 
order to be accessible for activating mechanisms, LLC is first released from ECM 
deposits. LTBP-molecules contain protease sensitive regions, like the N-terminal hinge-
region, which are targeted by proteolytic enzymes including plasmin, thrombin, mast cell 
chymase, leucocyte elastase and BMP-1 (Taipale et al., 1992; Taipale et al., 1995; Ge and 
Greenspan, 2006). Alternatively, TGF-β can be directly released from the ECM. In vitro, 
the liberation of LLC has been shown to occur also via replacement of ECM bound LLC 
by fibrillin-1 fragments, which bind the same N-terminal region of fibrillin-1 (Chaudhry et 
al., 2007). Similar competitive binding to fibrillin-1 has been observed also between 
LTBP-1 and the non-TGF-β binding LTBP-2 (Hirani et al., 2007). There appear to be 
various mechanisms that reveal the receptor binding epitopes and thus there are different 
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ways to activate TGF-β. Only some of the details of these complex processes are currently 
understood. On the cell surface there are integrins, which recognize the LAP part in LLC 
or SLC. Conformational changes induced by integrin binding finally release the TGF-β 
dimer. The integrins αvβ6 and αvβ8 are examples of receptors recognizing the RGD 
sequence of LAP (Munger et al., 1999; Mu et al., 2002). It has been suggested that αvβ6 
integrin, together with matrix bound LTBP-1, create mechanical tension, which could 
disturb the interaction between LAP and TGF-β (Annes et al., 2004). The expression of 
αvβ6 is highly upregulated in response to tissue injury and inflammation. αvβ8 mediated 
TGF-β activation instead is MT1-MMP dependent and is critical for brain vessel 
homeostasis (Cambier et al., 2005). It appears that the integrin mediated activation of 
TGF-β is important in vivo, as a mouse having the RGD mutation in TGF-β phenocopies 
the major features of TGFβ1 null mouse (Yang et al., 2007). In addition, mice lacking αvβ6 
and αvβ8 integrins develop similar abnormalities than TGF-β1(-/-) and TGF-β3(-/-) mice 
(Aluwihare et al., 2009). There is also evidence that integrins αvβ3 and αvβ5 may be 
involved in mediating the activation of TGF-β1 during the progression of fibrotic 
disorders, like scleroderma (Asano et al., 2005; Asano et al., 2006; Scotton et al., 2009). 
Since LAP-β2 does not contain the integrin binding RGD-sequence, it must therefore be 
activated by other means. In addition to integrins, the matricellular protein 
trombospondin-1 can activate TGF-β in vivo (Crawford et al., 1998). The mechanism 
involves conformational changes induced by binding of trombospondin-1 to the N-
terminal region of LAP. This activation applies to all TGF-β isoforms (Ribeiro et al., 
1999). Proteolytic enzymes like plasmin and MMPs have been considered as important 
activators of TGF-β, but their role in vivo is not so clear. LAP cleavage by MMP-2 has 
been reported to follow BMP-1 mediated LLC release from the ECM (Ge and Greenspan, 
2006). 
1.2.4 TGF-β signaling 
TGF-β family ligands signal through heteromeric receptor complexes, which contain type 
I and type II receptors with serine/threonine kinase activity. In humans there are seven 
type I receptors (ALKs 1-7) and five type II receptors (ActR-IIa, Act-IIB, BMPRII, 
AMHRII and TβRII), which are traditionally believed to exist as homodimers within the 
receptor complex. However, there is accumulating evidence to indicate that two different 
type I receptors within the same receptor complex exist widely in different cell types 
(Goumans et al., 2003; Daly et al., 2008; Little and Mullins, 2009). The specific sequences 
of type I receptors define which downstream receptor Smads (R-Smads) can be recruited. 
ALK1, 2, 3 and 6 bind Smads 1, 5 and 8, whereas ALK4, 5 and 7 bind Smad2 and Smad3. 
The growth inhibitory effects of TGF-β are mediated through TβRII and ALK5, which 
phosphorylate Smad2 and Smad3 (Fig. 4). It is now accepted that TGF-β also activates 
traditional BMP targets Smad1 and 5 via ALK1, 2 or 3, through which it triggers 
endothelial cell migration and proliferation (ALK1) (Goumans et al., 2002) or anchorage 
independent growth (ALK2, ALK3) (Daly et al., 2008). Although Smad pathways 
comprise an important part of TGF-β signaling, there are other crucial pathways, like the 
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MAPK pathways, activated by TGF-β as well (Fig.4) (Moustakas and Heldin, 2005). 
Importantly, there is significant crosstalk between the Smad and non-Smad pathways, 
indicating that TGF-β signaling is regulated by complex networks. 
1.2.4.1 Classical Smad pathway 
In addition to signaling receptors there are coreceptors in mammals, such as endoglin and 
betaglycan, which can either facilitate or limit TGF-β signaling. On the cell surface, 
betaglycan is required for the efficient TGF-β2/TβRII interaction, which otherwise occurs 
with low affinity (Sankar et al., 1995). However, in its soluble form, betaglycan 
antagonizes TGF-β activity (López-Casillas et al., 1994). Ligand binding to the signaling 
receptors induces the formation of a heteromeric receptor complex, allowing the 
constitutively active type II receptor to transphosphorylate the regulatory GS domain of 
type I receptor, which is close to the serine-threonine kinase domain (Moustakas and 
Heldin, 2009; Padua and Massagué, 2009). As a consequence of phosphorylation, R-
Smads are recruited to the receptor complex through their C-terminal MH2 domain. This 
interaction is facilitated by membrane bound protein SARA (Smad anchor for receptor 
activation). Once phosphorylated, activated R-Smads associate with the common mediator 
Smad (Co-Smad), which is Smad4 in mammals. The R-Smads in the resulting complex 
are either homodimers or heterodimers containing Smads 1, 2, 3 or 5 in different 
combinations. The Smad complex is translocated into the nucleus, where it either directly 
or with the help of other transcription factors, binds to chromatin (see section 1.4.3.1). The 
Smad MH1 domain recognizes the CAGA DNA-sequence, but the binding affinity is 
rather low. Therefore, the Smad complex recruits cofactors like RUNX, E2F, AP1, 
CREB/ATF and others to efficiently interact with DNA (Massagué and Gomis, 2006). The 
binding of transcriptional coactivators or corepressors to the complex ultimately define the 
transcriptional activity of the target gene. The expression of these various Smad binding 
partners is cell-type and context-dependent, accounting for the different signaling 
outcomes that can be induced by TGF-β. 
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Figure 4. TGF-β signaling. Smad and non-Smad signaling pathways downstream of the TGF-
β receptors. Based on (Miyazono, 2009; Moustakas and Heldin, 2009). 
1.2.4.2 MAPK pathway 
TGF-β signals also via non-Smad pathways, some of which control Erk, JNK and p38 
mitogen-activated protein kinases (MAPK). The MAPK pathways are composed of 
protein kinase cascades, which act in a hierarchical manner to ultimately phosphorylate 
target molecules including nuclear transcription factors.  
TβRI and TβRII are dual-specificity kinases, which in addition to their strong serine-
threonine kinase activity possess a weak tyrosine kinase activity (Lawler et al., 1997; Lee 
et al., 2007). These characteristics are critical for the TGF-β stimulated Erk activation 
cascade, which is initiated by phosphorylation of ShcA adaptor protein on its specific 
serine and tyrosine residues by TβRI (Lee et al., 2007). This occurs on a receptor complex 
including TβRII, which probably mediates TβRI tyrosine phosphorylation and activation. 
The phosphorylated ShcA associates with adaptor protein Grb2 and GTP-exchange factor 
Sos, leading to activation of the MAPK signaling cascade (Ras-Raf-MEK-Erk). Erk1/2 
can phosphorylate over 100 possible substrates, which modulate a number of cellular 
functions (Ramos, 2008). It has been demonstrated that Erk activation by TGF-β is modest 
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compared to activation achieved by receptor tyrosine kinases (Mulder, 2000). This may be 
important with respect to the signaling specificity. Furthermore, MAPK pathways act in 
concert with the Smad pathway (Javelaud and Mauviel, 2005). Erk can either directly 
phosphorylate Smads to control their activity (Uchida et al., 2001; Hayashida et al., 2003) 
or regulate the expression of Smad cofactors, like AP-1 elements (Shaulian and Karin, 
2001). Signaling crosstalk between the MAPK and Smad pathways plays a role during 
TGF-β-induced EMT (Davies et al., 2005). 
In contrast to Erk activation by TGF-β, the activation of the p38 and JNK MAPK 
pathways occurs independently of kinase activity (Sorrentino et al., 2008; Yamashita et 
al., 2008). Upon ligand binding to the TβRII TRAF6 (tumor necrosis factor α receptor-
associated factor) is recruited to the cytoplasmic domain of TβRI. As a result, TRAF6 is 
autoubiquitylated, which in turn leads to the polyubiquitylation of TAK1 (TGF-β-
associated kinase), a MAP3K acting upstream of p38 and JNK. Smad7 likely facilitates 
the activation of this MAPK pathway, serving as a scaffolding protein (Sorrentino et al., 
2008). TGF-β induces apoptosis via the TRAF6-TAK1-p38/JNK pathway. 
1.3 Latent TGF-β binding proteins 
1.3.1 Structural characteristics of LTBPs 
Four LTBPs (LTBPs 1-4) with their characteristic properties have been identified and 
molecularly cloned (Kanzaki et al., 1990; Morén et al., 1994; Yin et al., 1995; Saharinen 
et al., 1998; Penttinen et al., 2002). Together with fibrillins 1-3 (Sakai et al., 1986; Zhang 
et al., 1994; Corson et al., 2004) they constitute the LTBP/fibrillin family of ECM proteins 
(Fig. 5). These large glycoproteins (LTBPs 125-240 kDa; fibrillins ~350 kDa) are 
characterized by varying degrees of cysteine-rich domains categorized into the EGF-like 
repeats, hybrid domains and 8-Cys repeats. The 8-Cys repeat is the hallmark of the 
LTBP/fibrillin family not found elsewhere. In LTBPs -1, -3 and -4 the 3rd 8-Cys repeat 
covalently associates with the small latent TGF-β complex (SLC) (see chapter 1.2.2), 
whereas in LTBP-2 and fibrillins, the minor structural differences within this domain 
impair the interaction. Based on molecular modeling, the critical region for TGF-β binding 
appears to be more hydrophobic as a result of two amino acid insertions leading to loss of 
hydrogen bonds, which would otherwise stabilize the structure (Saharinen and Keski-Oja, 
2000). The non-TGF-β binding 8-Cys repeats may have significance in ECM targeting, as 
described for LTBP-1 (Unsöld et al., 2001). Interestingly, a recent study described a 
severe human syndrome caused by mutations affecting either hybrid or 8-Cys domains of 
LTBP-4 (Urban et al., 2009). The EGF-like domains are the main structural domains in 
LTBPs and particularly in the central regions of the molecule, they are Ca2+ binding type. 
In fibrillins, Ca2+ binding is critical for stabilizing the rod-like conformation of EGF-like 
domains and protecting them from proteolysis (Handford, 2000). The EGF-like domains 
are also abundant in many other ECM proteins and have been reported to mediate protein-
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protein interactions in addition to their involvement in EGFR-mediated signaling (Adam 
et al., 1997; Tran et al., 2005). Hybrid domains share similarities with 8-Cys repeats and 
EGF-like domains. One characteristic of LTBPs are regions with a high proline-content. In 
LTBP-4, the proline-rich region near the C-terminus is particularly long compared to the 
other family members (Saharinen et al., 1998). The proline-rich hinge-region is a likely 
target for proteolytic cleavage, which can release ECM bound LLC (Taipale et al., 1994). 
Structural variations are common among LTBPs. In particular the N-terminal domain 
is subject to variations. N-terminally extended forms have been identified for LTBPs-1 
and -4. Since the N-terminal domain of LTBPs is important for ECM targeting (Olofsson 
et al., 1995; Koli et al., 2005), these variations are believed to affect ECM binding 
specificities. The long form of LTBP-1 (LTBP-1L) associates more efficiently with the 
ECM compared to the shorter variant (LTBP-1S) (Olofsson et al., 1995). Another major 
target for structural variability is the long stretch of EGF-like repeats, in which the number 
of these motifs can vary. LTBP-4Δ8-Cys represents another type of splice variant, which 
due to the lack of the 3rd 8-Cys repeat, is unable to bind TGF-β (Koli et al., 2001). The 
reason for this structural diversity is not completely understood, but it likely reflects the 
importance of LTBPs in fine-tuning TGF-β targeting and activation. 
 
Figure 5. LTBP/fibrillin family. Modified from (Saharinen and Keski-Oja, 2000).   
1.3.2 Biological roles and disease associations 
LTBPs are widely expressed in human tissues. All LTBPs are found in human heart and 
skeletal muscle. In other tissues and organs, their expression patterns overlap only 
partially. LTBP-1L is expressed in the heart, placenta, kidney and prostate, whereas 
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LTBP-1S displays a wider tissue distribution and is additionally expressed in the lung, 
skeletal muscle, testis and ovary (Olofsson et al., 1995). LTBP-2 is predominantly 
expressed in the lung (Morén et al., 1994). LTBP-3 expression is highest in heart, skeletal 
muscle, prostate and ovaries (Penttinen et al., 2002). Prominent LTBP-4 expression has 
been detected in heart, skeletal muscle, pancreas, uterus and small intestine and at 
moderate levels in lung and placenta (Giltay et al., 1997; Saharinen et al., 1998). 
LTBPs play a critical role in TGF-β biology, especially in its targeting and activation. 
LTBPs are for example required for the assembly and efficient secretion of TGF-β 
(Miyazono et al., 1991) and for the subsequent deposition as a latent complex into the 
ECM (Taipale et al., 1994). Further, LTBPs are targets for proteolytic cleavage, which 
decreases the amount of ECM bound latent TGF-β and consequently increases the 
accessibility of the latent complex to activating mechanisms. The correct binding of the 
LLC to the ECM is also crucially required for certain activation mechanisms (Annes et al., 
2004). The interaction between the hinge region of LTBP-1 and FN is a prerequisite for 
the αvβ6-mediated TGF-β activation (Fontana et al., 2005). In addition to in vitro studies, 
the phenotypes of LTBP knockout or hypomorphic mice have been mainly consistent with 
the dysregulated TGF-β activation. Ltbp1L null mice have severe developmental defects in 
the cardiac outflow tract due to decreased TGF-β activity. In Ltbp3 null mice, the skull 
and long bones develop abnormally (Dabovic et al., 2002), which is in line with 
observations that TGF-β can inhibit hypertrophic chondrocyte differentiation via 
stimulation of parathyroid hormone related protein and is also required for normal bone 
physiology. The disruption of the Ltbp-4 gene in mice evokes pulmonary emphysema, 
cardiomyopathy and colorectal cancer (Sterner-Kock et al., 2002). The decreased 
alveologenesis in Ltbp4S -/- lungs has been interpreted as a consequence of increased 
rather than decreased TGF-β activity, highlighting the complexity of the mechanisms 
regulating the activation of TGF-β (Dabovic et al., 2009). Ltbp-2 is vital for early 
development as reflected in the embryonic lethality of Ltbp2-/- mice (Shipley et al., 2000). 
In view of the fact that LTBPs are usually secreted in excess to TGF-β at least in vitro 
and apparently have functions not related to TGF-β biology, there is only a limited amount 
of evidence about these other roles of LTBPs. Interestingly, LTBP-2 can modulate cell 
adhesion (Hyytiäinen and Keski-Oja, 2003; Vehviläinen et al., 2003). In addition, LTBPs-
2 and -4 are involved in elastogenesis (Hirai et al., 2007; Dabovic et al., 2009). 
Disease associations of LTBPs are starting to emerge. In humans, LTBP2 is now 
accepted as a candidate gene which is disturbed in primary congenital glaucoma (Ali et al., 
2009). It was proposed that LTBP-2 has an important structural role in the ciliary body of 
the eye. The affected individuals also showed varying degrees of osteopenia. A single-
nucleotide polymorphism within the LTBP2 gene has been linked to bone mineral density 
variation and fracture (Cheung et al., 2008). Interestingly, LTBP-2 is highly expressed in 
human bone marrow derived mesenchymal stem cells (Koli et al., 2008). A mutation in 
the LTBP3 gene is also associated with bone abnormalities. A homozygous nonsense 
mutation (Y774X) within a region coding one of the EGF-like repeats of LTBP-3 is 
associated with oligodontia, increased bone density and scoliosis (Noor et al., 2009), 
likely reflecting the crucial role of LTBP-3 in regulating the TGF-β bioavailability. LTBP4 
mutations result in the most severe LTBP-associated disease described to date. This 
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syndrome affects multiple organs including the pulmonary, gastrointestinal, genitourinary 
and musculoskeletal systems as well as skin and is associated with a high mortality rate in 
infancy and early childhood (Urban et al., 2009). The severe clinical outcomes of this 
syndrome originate from increased active TGF-β and the disorganization of elastic fibers.  
1.3.3 Interactions with other ECM constituents 
The importance of LTBPs in the ECM targeting and activation of TGF-β is well 
recognized, but the interactions between LTBPs and other ECM constituents directing 
these processes are only beginning to be understood. It appears that different LTBP 
isoforms differ in their ECM binding preferences, thus creating diversity in the ECM 
associated TGF-β deposits. Fibrillins are integral constituents of ECM microfibrils, which 
are widespread in different connective tissues, either associated with elastin to form elastic 
fibers or as independent elastin-free assemblies. LTBPs-1, -2 and -4 codistribute with 
fibrillin microfibrils in tissues (Gibson et al., 1995; Dallas et al., 2000; Ono et al., 2009) 
and there is evidence to indicate that these proteins interact directly (Isogai et al., 2003; 
Hirani et al., 2007). Therefore, fibrillin microfibrils are considered as an important storage 
place for latent TGF-β. The proper structure of microfibrils is critical for maintaining the 
balance in TGF-β activation. 
The assembly of fibrillin microfibril occurs pericellularly and depends on FN 
fibrillogenesis (Kinsey et al., 2008; Sabatier et al., 2009). The colocalization of fibrillin 
with FN is prominent in the early phases of ECM assembly. Furthermore, interactions 
with HSPGs direct the ECM deposition of fibrillins (Tiedemann et al., 2001; Ritty et al., 
2003). LTBPs also initially colocalize with FN in cell culture, but later on they form 
distinct fibrillar networks (Dallas et al., 2005; Koli et al., 2005; Vehviläinen et al., 2009). 
FN is critically required for LTBP-1 ECM assembly to occur (Dallas et al., 2005). The 
LTBP-1/FN interaction employs the N-terminal domain of LTBP-1 (aa 67-487) and it 
appears to be mediated by HSPGs (Chen et al., 2007). Interestingly, cells actively 
reorganize fibrillar ECM (Sivakumar et al., 2006). As a result, LTBPs codistribute with 
fibrillins (Ramirez and Rifkin, 2009). In the absence of fibrillin-1, rat osteosarcoma cells 
deposit LTBP-1 into the ECM (Dallas et al., 2005), whereas in cell cultures of neonatal 
dermal fibroblasts fibrillin-1 was indispensable for the ECM deposition of LTBPs-1 and -
4 (Ono et al., 2009). Furthermore, LTBP-2 deposition depends on fibrillin-1 (Vehviläinen 
et al., 2009). 
A number of studies have examined the interactions between LTBPs and fibrillins. The 
fibrillin-1 binding site resides in the C-terminal end of LTBPs-1, -2 and -4 (Isogai et al., 
2003; Hirani et al., 2007), whereas the corresponding region in LTBP-3 does not bind 
fibrillin-1 (Isogai et al., 2003). LTBP-1 binds also the N-terminal domain of fibrillin-2 in 
vitro (Isogai et al., 2003), whereas LTBP-2 does not (Hirani et al., 2007). The C-terminal 
LTBP-2 fragment competes with analogous LTBP-1 fragment in binding to fibrillin-1, 
suggesting that LTBP-2, which does not bind TGF-β, could indirectly regulate TGF-β 
deposition on microfibrils (Hirani et al., 2007). 
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1.4 Transcriptional regulation of gene expression 
Proper spatial and temporal expression of genes is a requirement for accurate cellular 
functions during development and in an adult organism for the maintenance of tissue 
homeostasis. Further, it enables cells to adapt to changing conditions in their environment. 
The regulation of eukaryotic gene expression occurs at variable levels, though the 
transcriptional initiation represents the main regulatory step. Transcriptional regulatory 
elements, generally located upstream from the transcription start site (TSS), are targeted 
by transcription factors, which in turn bind a variety of other regulatory proteins termed 
coactivators or corepressors. The synergistic function of all these factors contributes to the 
initiation or repression of gene expression. The promoter is a key regulatory unit, located 
at the 5’-end of its transcribed sequence, which ultimately determines the initiation of 
transcription. Since gene expression is elicited as a result of interactions between 
multitude of proteins, its vulnerability to alterations is evident. Indeed, a number of human 
diseases are associated with mutations or chromosomal translocations of either 
transcriptional regulatory elements or transcription factors. Therefore, in order to 
understand the molecular biology behind these pathologies and to target them 
therapeutically, it is critical to identify the regulatory elements which control gene 
expression. The initiation of eukaryotic gene transcription, specific promoter features and 
Smad transcription factors as an example of transcriptional regulators of ECM genes are 
discussed below. 
1.4.1 Initiation of transcription 
The course of events preceding the initiation of transcription is directed by interactions 
between trans-acting transcription factors and cis-acting regulatory elements on gene 
promoter. The promoter can be divided into two functionally distinct entities: a core 
promoter immediately surrounding the TSS and a proximal promoter extending upstream 
from the core promoter. The specific sequence elements on the core promoter are 
recognized by general transcription factors (GTF) or their associated proteins, which in 
turn induce the formation of a larger protein assembly referred to as the preinitiation 
complex (PIC) (Maston et al., 2006). In addition to GTFs (TFIIA, TFIIB, TFIID, TFIIE, 
TFIIF and TFIIH) PIC includes RNA polymerase II (RNAPII), which needs to be 
correctly positioned with the help of PIC constituents and other regulatory proteins in 
order to initiate RNA synthesis. Mediator is a modular protein complex, which stabilizes 
the PIC structure and is critically required for basal and activated transcription (Takagi 
and Kornberg, 2006). The detailed mechanism how Mediator promotes the initiation of 
transcription is unknown, but based on structural studies, TBP (TATA binding protein) 
appears to induce a conformational change on Mediator, which favors the interaction with 
RNAPII (Cai et al., 2010). Mediator also interacts with transcription factors and thus 
transmits regulatory signals to RNAPII. On its own, PIC assembled on the core promoter 
can maintain a minimal transcriptional activity (basal transcription). In order to achieve 
higher levels of activity, contacts between PIC and transcription factors/coactivators 
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located on the proximal promoter are required. Transcription factors/coactivators not only 
promote PIC organization, but likely affect the chromatin structure so that it becomes 
accessible to the transcriptional machinery. How these covalent modifications of histones 
(acetylation, methylation, phosphorylation) contribute to the reorganization of the 
chromatin structure is under active research at the moment. 
1.4.2 Regulatory elements within a promoter sequence 
Promoter characterization by sequence analysis attempts to identify conserved sequence 
elements, which serve as recognition sites for the basal transcriptional machinery or for 
transcription factors. Several core promoter elements have been identified, most of these 
are TFIID-interaction sites. A classical example is the TATA box (consensus sequence: 
TATAWAAR), which resides 25-30 bp upstream of the TSS. It was once considered as a 
universal core promoter element, but is actually present in only about 20% of human 
promoters (Tokusumi et al., 2007). Other quite common core promoter elements identified 
are the initiator element (Inr, YYANWYY) surrounding the TSS and the downstream 
promoter element (DPE, RGWYV) located 28-32 bp downstream of the TSS (Smale and 
Baltimore, 1989; Kadonaga, 2002). Both of them are recognized by the TAF subunits of 
TFIID. Although the Inr can function independently of the TATA box, together they can 
act synergistically. The more infrequent core promoter elements BRE (the TFIIB 
recognition element) (Lagrange et al., 1998; Deng and Roberts, 2005) and MTE (the motif 
ten element) (Lim et al., 2004) are not directly bound with TFIID, but they coexist with 
other TFIID-binding elements. The most common feature of human promoters is the 
presence of CpG islands, which are short stretches of DNA with a high content of CG 
dinucleotides. CpG islands are usually unmethylated, whereas elsewhere in the genome 
the methylation of these dinucleotides is believed to stabilize the chromatin structure. CpG 
islands are typically found on TATAless promoters, which control ubiquitous gene 
expression. As many as 72% of human promoters have a high CpG content (Saxonov et 
al., 2006). 
The development of new sequencing-based high throughput methods during the recent 
years has revolutionized the view about the structure and function of the core promoter. 
The cap analysis of gene expression (CAGE) technology has enabled large scale TSS 
identification from human and mouse genomes. A study utilizing this technology revealed 
that human and mouse core promoters can be categorized into sharp and broad promoters 
(Carninci et al., 2006). Instead of having a single TSS, the majority of strong human and 
mouse core promoters have an array of TSSs distributed over a region of 50-100 
nucleotides. Consequently, they are referred to as broad promoters. The sharp promoters 
typically have a TATA box and an Inr element and only single, sharply defined TSS 
(Sandelin et al., 2007). Broad promoters are mainly TATAless, but rich in CpG islands. 
Sharp promoters more often control tissue-specific gene expression, whereas broad 
promoters generally regulate ubiquitously expressed genes. In addition, it has been 
observed that multiple TSS usage is associated with the exclusion of ATG start codons 
from a region extending 1 kb upstream and downstream of the main regions of 
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transcription initiation referred to as ATG deserts (Lee et al., 2005). It has become clear 
that the core promoter elements mentioned above are not universal and that there are core 
promoters, which lack all of them. Moreover, taking into account the fact that the known 
core promoter elements are typical for sharp promoters, which the majority of vertebrate 
promoters do not represent, we have only a limited amount of information available on the 
transcriptional regulation of human genes. Future studies are likely to reveal new core 
promoter elements, which define transcription initiation on broad promoters. 
1.4.3 Transcriptional regulators 
1.4.3.1 Smad transcription factors 
Smad transcription factors are key mediators in TGF-β signal transduction (chapter 
1.2.4.1). Smad binding elements (SBE) have been identified among others within the 
promoter regions of various ECM genes (Verrecchia and Mauviel, 2002). R-Smad and 
Co-Smad proteins consist of two globular, highly conserved MH1 and MH2 (Mad-
homology) domains, which are connected by a variable linker region. In addition to 
binding sites for other molecules, the linker region contains phosphorylation sites, via 
which Smad activity can be controlled by other signaling pathways. The SSXS 
phosphorylation site for receptor-mediated activation resides in the C-terminal MH2 
domain instead. The MH2 domain is also important in mediating interactions between 
Smads and other transcription factors, whereas the MH1 domain can directly bind to 
DNA. The DNA binding activity is established by a β-hairpin structure which allows 
hydrogen bond formation with the SBE, 5’-CAGA-3’ (Shi et al., 1998; Zawel et al., 
1998). Smad2 has an insert in its MH1 domain, which disrupts DNA binding ability. 
Therefore, it recruits other DNA binding cofactors to control its target genes. DNA 
binding cofactors are utilized by other Smads as well in order to increase the affinity and 
selectivity of a particular Smad-DNA interaction. A number of Smad-interacting cofactors 
have been identified; these are representatives of diverse transcription factor families, thus 
reflecting the versatility of TGF-β signaling. Examples of these Smad cofactors include c-
Fos, c-Jun, JunB and JunD transcription factors of bZIP family, Sp1 and GATA 
transcription factors representing Zinc finger proteins and the representatives of the Runx 
family transcription factors, Runx1-3 (Feng and Derynck, 2005). Nuclear complexes 
containing Smads and associated cofactors attract additional coactivators or corepressors, 
which eventually determine the transcriptional response. CREB binding protein (CBP) and 
p300 are Smad coactivators capable for histone acetylation (Chan and La Thangue, 2001). 
Many of the Smad corepressors like TG3-interacting factor (TGIF) and c-Ski recruit 
chromatin-condensating histone deacetylases (Feng and Derynck, 2005). In addition, 
TGIF competes with coactivators for binding to R-Smads, whereas c-Ski disrupts the 
formation of functional R-Smad/Smad4 complex via its interactions with both Smad 
constituents (Wotton et al., 1999; Wu et al., 2002). Smads can also directly inhibit gene 
expression by binding to other transcription factors and thereby preventing their 
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association with coactivators or DNA (Liu et al., 2001; Liu et al., 2004). It has been 
demonstrated that the inhibitory Smads (Smad6, Smad7) act as transcriptional repressors 
in addition to their role in inhibiting R-Smad phosphorylation at the receptor complex 
(Yan et al., 2009). In the nucleus, the TGF-β pathway inhibitor, Smad7, disrupts the 
formation of a functional Smad-DNA complex (Zhang et al., 2007). 
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2 Aims of the study 
At the time this study was started, only the transcriptional regulation of LTBP-1 had been 
analyzed (Koski et al., 1999). Since the knowledge about the mechanisms that control the 
expression of a particular gene is fundamental for the deeper understanding of the tissue-
specific functions of the proteins, it was decided to explore possible differences between 
the transcriptional regulation of LTBP genes. The characterization of the LTBP-3 promoter 
region was an intriguing starting point, since Ltbp3 null mice develop skeletal defects like 
osteosclerosis and osteoarthritis. Subsequently, this study concentrated on LTBP-4S, 
which was previously found to have very specific functions in mouse tissues. Ltbp4 null 
mice display symptoms partially related to disturbed TGF-β signaling. Our aim was to 
examine the ECM targeting of LTBP-4S, which, based on a mouse model, appeared to be 
critical for the proper activation of TGF-β. Particularly, it was of interest to analyze 
LTBP-4/FN interaction, as it had been earlier shown that these proteins initially colocalize 
in the cell culture. In addition to FN binding capacity, heparin binding sites were found on 
LTBP-4. Thus it was decided to study whether LTBP-4S could mediate cell adhesion, a 
property previously linked to LTBP-2. Later on, the studies were extended to apply to 
LTBP-4L as well. It was felt interesting to identify differences/similarities between these 
two N-terminal variants of LTBP-4. Since the N-terminal domain is important for the 
ECM deposition of LTBPs, one special interest was to examine how this N-terminal 
extension of LTBP-4 affects on its ECM targeting and consequently on TGF-β activation. 
Another goal was to characterize, whether two independent promoters regulate the 
expression of LTBP-4S and -4L, which is true for LTBP-1 N-terminal variants. For these 
reasons, the aims of this thesis were: 
 
1. to characterize the promoter region of LTBP-3 gene and identify factors regulating its 
transcription 
 
2. to examine the ECM targeting of LTBP-4S and identify binding sites for other ECM 
constituents. Based on these findings, the analysis of the potential role of LTBP-4 in cell 
adhesion was set as an additional goal. 
 
3. to analyze whether independent promoters regulate the expression of the N-terminal 
variants of LTBP-4. 
 
4. to identify differences/similarities between LTBP-4S and -4L. Particularly, it was 
intended to define the ECM targeting of LTBP-4L and its importance for TGF-β biology.  
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3 Materials and methods 
3.1 Cell lines and reagents 
All cell lines were maintained in Dulbecco’s modified Eagle’s medium (D-MEM) or 
Eagle’s minimal essential medium (MEM) supplemented with 10% (v/v) fetal bovine 
serum (FBS) (Euroclone, Siziano,Italy) or with 5% FN-depleted FBS.The cell lines used 
are listed in Table I with their American Type Culture Collection (ATCC, Manassas, VA, 
USA) reference number or reference. 
 
Table I. Cell lines 
Cell line Description Reference number or reference 
MG-63 human osteosarcoma cell line ATCC: CRL-1427 
Saos-2 human osteosarcoma cell line ATCC: HTB-85 
HaCat immortalized human keratinocytes (Boukamp et al., 1988) 
CCL-137 human embryonic lung fibroblasts ATCC: CCL-137 
HT-1080 human fibrosarcoma cell line ATCC: CCL-121 
Bowes human melanoma cell line ATCC: CRL-9607 
MEF, FN+/+ mouse embryonic fibroblasts, wild type Dr. Reinhard Fässler, Max Planck 
Institute of Biochemistry, 
Martinsried, Germany, (Sakai et al., 
2001) 
MEF, FN-/- mouse embryonic fibroblasts, FN deficient Dr. Reinhard Fässler 
CHO Chinese hamster ovary  cells ATCC: CCL-61 
A549 human lung adenocarcinoma cell line ATCC: CCL-185 
HepG2 human hepatocellular carcinoma cell line ATCC: HB-8065 
 
 
The antibodies and other reagents used in this study are listed in Tables II and III, 
respectively, with the reference to the manufacturer or provider. 
 
Table II. Antibodies 
Antigen Description Reference 
LTBP-1 rabbit polyclonal ab (Ab39) Dr. Carl-Henrik Heldin, Ludwig 
Institute for Cancer Research, 
Uppsala, Sweden 
LTBP-4 rabbit polyclonal ab (Saharinen et al., 1998) 
LTBP-4 mouse monoclonal ab (Koli et al., 2005) 
LAP-β1 goat polyclonal ab R&D Systems, Minneapolis, MN, 
USA 
FN rabbit polyclonal ab (F3648) Sigma, St. Louis, MO, USA 
FN mouse monoclonal (FN-15) Sigma, St. Louis, MO, USA 
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fibrillin-1 rabbit polyclonal (9543) Dr Lynn Sakai, Oregon Health and 
Science University, Portland, 
Oregon, USA 
influenza hemagglutinin 
epitope 
mouse monoclonal Covance, Princeton, NJ, USA 
FLAG epitope rabbit polyclonal (F7425) Sigma, St. Louis, MO, USA 
 
Table III. Enzymes, growth factors, hormones and other reagents 
Reagent Manufacturer Study 
restriction enzymes New England BioLabs, Ipswich, MA, USA I, II, III 
oligonucleotides TAG Copenhagen A/S, Copenhagen, Denmark I 
oligonucleotides Oligomer Oy, Helsinki, Finland III 
AmpliTaq Gold DNA polymerase Applied Biosystems, Foster City, CA, USA I, II, III 
Phusion High-Fidelity DNA 
polymerase 
Finnzymes, Espoo, Finland III 
ligases Promega, Madison, WI, USA I, II, III 
Lipofectamine Promega, Madison, WI, USA II 
Fugene 6 transfection reagent Roche, Mannheim, Germany I, II, III 
Lipofectamine transfection reagent Promega, Madison, WI, USA II 
[α-32P]-dCTP GE Healthcare, Buckinghamshire, UK I, III 
TGF-β1 R&D Systems, Minneapolis, MN, USA I 
EGF R&D Systems, Minneapolis, MN, USA I 
BMP-2 R&D Systems, Minneapolis, MN, USA I 
BMP-4 R&D Systems, Minneapolis, MN, USA I 
bFGF R&D Systems, Minneapolis, MN, USA I 
1α25(OH)2D3 Sigma, St. Louis, MO, USA I 
25(OH)D3 Sigma, St. Louis, MO, USA I 
β-estradiol Sigma, St. Louis, MO, USA I 
tamoxifen Sigma, St. Louis, MO, USA I 
α-retinoic acid Sigma, St. Louis, MO, USA I 
dexamethasone Sigma, St. Louis, MO, USA I 
MEK Inhibitor U0126 Promega, Madison, WI, USA I 
JNK Inhibitor SP600125 Calbiochem, San Diego, CA, USA I 
p38 Inhibitor SB203580 Calbiochem, San Diego, CA, USA I 
heparin Sigma, St. Louis, MO, USA II 
heparin-sepharose 6 Fast Flow GE Healthcare, Buckinghamshire, UK II 
heparinase II Sigma, St. Louis, MO, USA II 
plasma FN Sigma, St. Louis, MO, USA II 
plasmin Sigma, St. Louis, MO, USA II 
n-octyl-β-d-glucopyranoside Sigma, St. Louis, MO, USA II 
Complete protease inhibitors Roche, Mannheim, Germany II, III 
1,2-phenylenediamine 
dihydrochloride 
Dako, Glostrup, Denmark II 
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3.2 Construction of expression vectors 
The constructions of expression plasmids designed or used in this study are summarized in 
Table IV with their references. 
 
Table IV. Expression plasmids  
LTBP-3 promoter    
name of the plasmid vector  insert study 
L3 PROM(-3014) pGL3-Basic -3014 – (-5) I 
L3 PROM(-2149) pGL3-Basic -2149 – (-5) I 
L3 PROM(-1538) pGL3-Basic -1538 – (-5) I 
L3PROM(-1195) pGL3-Basic -1195 – (-5) I 
L3PROM(-842) pGL3-Basic -842 – (-5) I 
L3PROM(-477) pGL3-Basic -477 – (-5) I 
L3PROM(-262) pGL3-Basic -262 – (-5) I 
L3PROM(-1195rev) pGL3-Basic -1195 – (-5) in reverse orientation I 
L3PROM-Smad3 pGL3-Basic -3014- (-5), mutation at -2739 I 
L3PROM-Smad3/AP1 pGL3-Basic -3014-(-5), mutations at -2739 and -2251 I 
 
LTBP-4 promoters    
LTBP-4S pGL3-Basic / pGL3-Enhancer -1112 – (+48) III 
LTBP-4S reverse pGL3-Basic / pGL3-Enhancer -1112 – (+48) reverse orientation III 
LTBP-4L pGL3-Basic / pGL3-Enhancer -1094 – (+63) III 
LTBP-4L reverse pGL3-Basic / pGL3-Enhancer -1094 – (+63) reverse orientation III 
 
cDNA constructs    
name of the plasmid vector insert (amino acids) study/reference 
LTBP-4S pEF-IRES-P full-length 1-1557 (Koli et al., 2004), II, III 
LTBP-4S/Δexon1 pEF-IRES-P 78-1557 II 
LTBP-4S/ΔN-term pEF-IRES-P 398-1557 II 
L4Ig1 Signal pIg plus 1-478 (Koli et al., 2005), II 
L4Ig2 Signal pIg plus 479-1066 (Koli et al., 2005), II 
L4Ig3 Signal pIg plus 1066-1551 (Koli et al., 2005), II 
LTBP-4S pSignal 1-1557 (Saharinen et al., 1998), 
II, III 
pTGF-β1 pcDNA3 full-length (Saharinen et al., 1996), 
III 
LTBP-4L pSignal full-length III 
LTBP-4L pEF-IRES-P full-length III 
LTBP-4S pFLAG-CMV-3 27-1557 III 
LTBP-4L pFLAG-CMV-3 28-1624 III 
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Figure 6. Schematic presentation of the recombinant LTBP-4 constructs. Modified from Fig. 2 
in II. 
The vectors used in this study are listed in Table V with the reference to the manufacturer. 
Table V. Vectors 
pRL-TK Promega, Madison, WI, USA 
pGEM-T-easy Promega, Madison, WI, USA 
pGL3-Basic Promega, Madison, WI, USA 
pGL3-Enhancer Promega, Madison, WI, USA 
pSignal (Saharinen et al., 1996) 
pEF-IRES-P (Hobbs et al., 1998) 
pBluescriptII KS Stratagene, La Jolla, CA, USA 
pFLAG-CMV-3 Sigma, St. Louis, MO, USA 
3.3 Production and purification of recombinant LTBP-4 (II) 
To produce full length LTBP-4S CHO cells were transfected with LTBP-4S/pSignal 
expression construct using Lipofectamine reagent. Neomycin-resistant clones expressing 
high levels of LTBP-4 were selected for recombinant protein production by dilution 
cloning. The purification of histidine-tagged LTBP-4 was performed as described 
(Hyytiäinen and Keski-Oja, 2003). Briefly, the secreted proteins were precipitated with 
40% (NH4)SO4 at +4°C. The precipitate was then dissolved in the column washing buffer 
(2 M urea, 300 mM NaCl, 50 mM Tris-HCl buffer, pH 7.2) and loaded onto a Talon metal 
chelate column (Clontech Laboratories, Mountain View, CA, USA). After washing, the 
bound proteins were eluted with the washing buffer containing 100 mM imidazole, which 
was followed by a buffer exchange to PBS using a Fast Desalting column HR 10/10 
(Amersham Pharmacia Biotech, Uppsala, Sweden). Finally, purified LTBP-4S was 
analyzed by Coomassie Blue protein staining and immunoblotting.  
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3.4 DNA analysis 
3.4.1 Transfection and promoter activity assay (I, III) 
One day before transfection, cells were seeded in 6-well plates, 3x105 cells per well. The 
transfection was carried out using Fugene 6 transfection reagent (Roche) together with the 
total of 2 µg of promoter constructs and pRL-TK control plasmid. After six hours, the 
fresh cell culture medium was changed. Serum-free culture medium was changed on the 
next morning when the growth factor and hormone stimulations were initiated. When the 
MAPK inhibitors were used, they were added 1 h before the addition of TGF-β1. After 
24h-stimulations, the cells were lysed and subjected to luciferase activity measurements 
using a Dual Luciferase Reporter Assay kit (Promega) and DCR-1 luminometer (MGM 
Instruments, Hamden, CT, USA).Without stimulations, the cells were grown for two days 
after transfection in the same culture media until they were lysed. The results are 
expressed as firefly luciferase activities normalized to the renilla luciferase value of the 
same sample. In the case of growth factor/hormone stimulations, the results are presented 
as fold induction compared to the untreated sample. 
3.5 RNA analysis 
3.5.1 RNA isolation and Northern hybridization (I, III) 
Total cellular RNA was isolated using RNeasy Mini kit (Qiagen, Valencia, CA, USA). 
The concentrations and purities of RNA samples were determined spectrophotometrically 
(BioPhotometer 6131, eppendorf, Hamburg, Germany). Total RNA was fractionated on 
0.8% agarose-formaldehyde gel and then transferred to Hybond-N nylon membrane 
(Amersham Pharmacia Biotech) or alternatively, commercial human MTN blots 
(Clontech, Mountain View, CA, USA) were used. cDNA probes for LTBP-3 or the N-
terminal variants of LTBP-4 were labeled with [α-32P]dCTP (GE Healthcare, 
Buckinghamshire, UK) by random priming. Hybridizations were performed in Express 
Hyb hybridization solution (Clontech, Mountain View, CA, USA) according to the 
instructions of the manufacturer. Finally, the membranes were washed under high 
stringency conditions and examined by autoradiography.  
3.5.2 RLM-RACE analyses of transcription initiation sites (I, III) 
Total cellular RNA was reverse transcribed to cDNA using Superscript II and random 
hexamer primers (Invitrogen, Carlsbad, CA, USA), or alternatively RACE-ready cDNAs 
from different human tissues (Ambion, Applied Biosystems, Foster City, CA, USA) were 
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used. The cDNA amplification with GC-rich PCR System (Roche, Mannheim, Germany) 
was performed according to RLM-RACE protocol. Reverse-primers were specific for a 
gene of interest, whereas the forward primers recognized the synthetic RNA-adapter 
ligated to the full-length mRNA molecules. The amplified products were analyzed by 
agarose gel electrophoresis, after which they were cloned to the pGEM-T-Easy T/A 
cloning vector (Promega, Madison,WI, USA) and sequenced. Multiple clones from three 
independent amplifications were analysed to locate the initiation sites of transcription. 
3.5.3 Quantitative PCR (III) 
The cDNAs were purchased from Applied Biosystems (Ambion). cDNA amplification 
was performed using TaqMan Assays-on-Demand gene expression products (Applied 
Biosystems, Foster City, CA, USA) and GeneAmp 7500 Sequence Detector thermal 
cycler (Applied Biosystems). The results have been presented as normalized to the mRNA 
levels of a gene with a constant expression (TBP). 
3.6 Protein analysis 
3.6.1 Collection of cell conditioned media (II, III) 
Confluent cell cultures were washed once with serum-free media, after which secreted 
proteins were collected for 24 or 48 h. Medium samples were clarified by centrifugation 
and where indicated, they were concentrated tenfold using Microcon YM-10 or YM-30 
centrifugal filter devices (Millipore, Billerica, MA, USA). To prevent protease activity, 
protease inhibitors (Complete, Roche) were added to each sample. Next, the samples were 
either immunoprecipitated and then analysed by SDS-PAGE and immunoblotting or 
directly analysed without immunoprecipitation. 
3.6.2 Isolation of ECM (II) 
The cells were grown for 12 d, after which the sodium deoxycholate insoluble matrices 
were isolated according to protocol described previously (Taipale et al., 1992; Taipale et 
al., 1994). In brief, the cell cultures were washed once with PBS and then treated with 
0.5% sodium deoxycholate in 50 mM Tris-HCl buffer, pH 8.0, containing 150 mM NaCl 
and 1% NP-40. To collect the insoluble material representing fibrillar ECM, the cells were 
scraped and the samples centrifuged at 8000 x g for 10 min. Next, the ECM preparations 
were washed once with ice-cold PBS and then digested with 0.3 U/ml of plasmin (Sigma) 
in PBS containing 1 mM MgCl2, 1 mM CaCl2 and 0.1% n-octyl-β-d-glucopyranoside 
(Sigma) at +37°C for 1 h to solubilize LTBPs. Protease inhibitors (Complete, Roche) were 
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then added and the supernatants clarified by centrifugation. Finally, the soluble proteins 
were analyzed by SDS-PAGE and immunoblotting.   
3.6.3 Immunoprecipitation (III) 
Secreted FLAG fusion proteins were harvested using anti-FLAG M2 affinity gel (Sigma) 
containing murine IgG1 monoclonal antibody. The samples were incubated with the 
affinity resin prepared according to the manufacturer’s instructions in a roller shaker for 2 
h at +4°C. The immunocomplexes were collected by centrifugation and were washed three 
times with Tris buffered saline (TBS). Next, the bound proteins were eluted either to 
reducing or nonreducing SDS-PAGE sample buffer by heating at 95°C for 3 min. The 
samples were clarified by centrifugation and then analyzed by SDS-PAGE and 
immunoblotting. 
3.6.4 SDS-PAGE and immunoblotting (II, III) 
Electrophoretic separation of proteins was carried out using commercial Tris-HCl 
polyacrylamide gels (Lonza, Walkerswille, MD, USA). Proteins were then transferred to 
nitrocellulose membranes using semi-dry blotting system (Biorad, Hercules, CA, USA). 
Before immunodetection, the membranes were incubated in 1% Triton X-100/PBS with 
5% nonfat milk to saturate nonspecific protein binding sites. Primary and secondary 
antibody incubations were next carried out in 0.05% Tween-20/TBS with 5% BSA for 1 h. 
After several washings, the binding of antibodies was detected using HRP-conjugated 
streptavidin and enhanced chemiluminescence (Amersham). 
3.6.5 Immunofluorescence analysis (II, III) 
The cells were grown on glass coverslips for the indicated times and then washed once 
with PBS. Next, the cells were fixed in ice-cold methanol at - 20°C. The cells were then 
washed three times with PBS followed by saturation of nonspecific binding sites with 3% 
BSA in PBS. The cells were incubated with the primary antibodies in Dulbecco’s PBS 
containing 0.5% BSA for 1 h. In order to detect the bound primary antibodies, the cells 
were incubated with Alexa Fluor conjugated secondary antibodies (Invitrogen, Carlsbad, 
CA, USA) for 1 h. Next, the coverslips were washed twice with Dulbecco’s PBS 
supplemented with 0.5% BSA. Finally, the coverslips were washed once in water and then 
mounted on glass slides using Vectashield anti-fading reagent (Vector Laboratories, 
Burlingame, CA, USA). The imaging of the samples was carried out using Axio-Cam HR 
camera (Carl Zeiss, Oberkochen, Germany) connected to the Axioplan 2 microscope 
(Zeiss) with AxioVision3.1 software (Zeiss).  
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3.6.6 Heparin binding assays (II) 
ÄKTA explorer HPLC instrument (Amersham Biociences) was used to run filtered 
conditioned medium from fibroblasts through the 1 ml HiTrap Heparin HP column 
(Amersham Biosciences) equilibrated with the 10 mM sodium phosphate buffer, pH 7.0. 
The column was washed until the absorbance returned to the baseline. Next, the bound 
proteins were eluted into the sodium phosphate buffer, pH 7.0 using increasing NaCl 
concentrations up to 1.5 M. The elution was carried out at the flow rate of 1 ml/min. 
Collected 1 ml fractions were analyzed by immunoblotting. Alternatively, heparin binding 
proteins were collected by incubating conditioned media with heparin Sepharose 6 Fast 
Flow (Amersham Biosciences) at room temperature for 2 h. Human plasma FN (20 µg/ml) 
and heparin (500 µg/ml) were added as indicated. The heparin Sepharose was washed 
three times with PBS containing protease inhibitors (Roche) and then once with PBS 
containing 300 mM NaCl. Finally, the bound proteins were eluted with NaCl in PBS. The 
eluted fractions were analysed by immunoblotting for the presence of LTBP-4 and FN.  
3.6.7 ELISA binding assays (II) 
Plates of 96 wells (MaxiSorp, Nunc) were coated with recombinant LTBP-4 or human 
plasma FN in PBS at +4°C for overnight. Nonspecific protein binding sites were saturated 
by incubating wells with 3% BSA in PBS for 2h. Next, the wells were washed with PBS 
containing 0.5% BSA, 1mM CaCl2 and 1 mM MgCl2, which was used in all subsequent 
washings and incubations. Human plasma FN (20 µg/ml) or serum-free cell conditioned 
media containing LTBP-4 was incubated in the wells for 1 h. Heparin was added at the 
same time where indicated. After the washings, the antibodies against FN or LTBP-4 were 
added for 1 h. Then HRP-conjugated secondary antibodies were incubated for 30 min, 
which was followed by addition of 1,2-phenylenediamine dihydrochloride (Dako). 
Finally, the reaction was stopped with H2SO4 and absorbances were measured at 450 nm. 
3.6.8 TGF-β activity assays (II) 
TGF-β activity in the conditioned media of MEFs was assessed using mink lung epithelial 
cells stably transfected with a PAI-1 promoter fragment fused to luciferase gene (TMLC). 
TMLCs which respond to TGF-β with luciferase activity, were provided by Dr. D. B. 
Rifkin (New York University School of Medicine, New York, USA). Heat treatment (80 
°C, 5 min) activates latent TGF-β and was used to determine the total TGF-β levels in 
medium samples. The TGF-β activity of standards and medium samples was analyzed as 
described (Abe et al., 1994). Alternatively, TMLCs were cocultured with MEFs for 
overnight, after which they were subjected to lysis and the luciferase activity assayed. The 
results have been expressed as relative values of TGF-β activity. 
 
 
 
 
48
3.7 Cell adhesion assays (II) 
Plates of 96 wells were coated overnight with the indicated proteins in PBS at +4°C. 
Nonspecific protein binding sites were saturated by incubating the wells with 1% heat-
denaturated BSA in PBS at room temperature for 2 h. The wells were washed once with 
PBS before the addition of cells. The cells were detached with trypsin-EDTA and 
suspended in serum-free medium, which was then either directly plated into the wells in 
triplicate (3x104 cells/well) or first treated with 2.5 U/ml heparinase II at +37°C for 30 
min. The cells were allowed to attach at +37°C for 1 h. Nonattached cells were removed 
by washing with PBS. The cells were then fixed and stained with 0.1% Coomassie Blue in 
10% acetic acid and 40% methanol and washed with the same fixative without the dye. 
Finally, the cells were lysed in 1% SDS in PBS and the absorbance was measured at 620 
nm. The results have been expressed relative to BSA control or alternatively relative to 
cell adhesion to FN. 
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4 Results and discussion 
4.1 Characterization of human LTBP-3 promoter (I) 
In order to analyze the transcriptional regulation of human LTBP-3 gene, a 3.0 kb DNA 
fragment upstream from the translation initiation site was cloned and its transcriptional 
activity analyzed in functional assays. The 5’-upstream region of LTBP-3 gene was 
examined by sequence analysis for the presence of sequence specific transcription factor 
binding sites and common core promoter elements. Furthermore, the transcription 
initiation sites were identified. 
4.1.1 Identification of potential regulatory elements within the LTBP-3 
promoter by sequence analysis 
TFSEARCH search program (Heinemeyer et al., 1998) was used to locate potential 
regulatory sequence elements within the upstream region of LTBP-3. No common core 
promoter elements for binding the basal transcriptional machinery, like the TATA box, 
were found. Instead, two MED-1 (multiple start site element downstream) sites, which are 
frequent in TATAless promoters (Ince and Scotto, 1995), were present within a region – 
79-(-194) bp upstream from the translation initiation site. Sequence analysis detected 
putative binding sites for representatives of the Sp1, AP-1 and Runx families of 
transcription factors, all of which are DNA binding cofactors of Smad transcription factors 
(Feng and Derynck, 2005). In addition, a consensus Smad-binding element 5’-CAGA-3´ 
was identified at position -2738. It has been reported that in addition to SBE, Smad 
transcription factors recognize additional GC-rich regions on promoters. Remarkably, the 
proximal region of LTBP-3 gene was found to be highly GC-rich. Sp1 transcription factors 
are ubiquitously expressed and they provide a basal transcription of many genes, including 
several ECM-related genes (Verrecchia et al., 2001b). In TATAless promoters, Sp1 can 
recruit TBP and the associated general transcription factor TFIID (Pugh and Tjian, 1991). 
AP-1 is a substrate for MAPKs, which phosphorylate and activate its Fos, Jun and ATF 
constituents. Erk 1/2 phosphorylates c-Fos, whereas JNK phosphorylates c-Jun, the main 
component of AP-1 complex (Javelaud and Mauviel, 2005). Furthermore, the linker 
region of Smads 2 and 3 is directly phosphorylated by Erk MAPKs preventing their 
nuclear translocation (Kretzschmar et al., 1999). As Ltbp3 null mice suffer from various 
skeletal abnormalities, the presence of binding sites for Runx1 within the LTBP-3 
upstream region was fascinating. While Runx2 has been recognized as a key regulator of 
osteoblast differentiation and chondrocyte maturation, the role of Runx1 in skeletal 
development has remained less clear. Recent evidence indicates that Runx1 regulates the 
differentiation of mesenchymal cells into chondrocytes, but is not essential for 
chondrocyte maturation, which is regulated by Runx2 (Kimura et al., 2010). The 
regulatory actions of Runx family members during chondrocyte differentiation are 
important for endochondral bone formation. Cooperative function of Runx1 and 2 has 
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been observed to promote sternal morphogenesis. In addition to its role in skeletal 
development, Runx1 is essential for definitive hematopoiesis (Miyazono et al., 2004). 
Binding sites for other transcription factors involved in hematopoietic differentiation, like 
c-Ets, MZF-1 and GATA family of transcription factors were identified on 5’-upstream 
region of LTBP-3. As Ltbp3 null mice display defects in thymus and spleen associated 
with reduced number of CD4/CD8 double positive T-cells in the thymus (Chen et al., 
2003), it could be speculated that the absence of LTBP-3 expression regulated by the 
hematopoietic transcription factors could contribute to changes in TGF-β activation, which 
is known to regulate T-cell development (Li et al., 2006). However, thymus and spleen 
defects in Ltbp3 null mice are interpreted to be consequences of the increased levels of 
corticosterones in the serum (Chen et al., 2003). 
In an attempt to locate the transcription initiation sites, RLM-RACE was performed 
using full-length cDNAs from human heart and MG-63 cells. The sequence analysis of the 
amplified products suggested that the transcription of LTBP-3 gene is initiated at several 
sites located -250- (-300) bp upstream from the translation initiation site. Multiple 
transcription initiation sites are typical to promoters devoid of a TATA box. Our 
observations about the distributed initiation of transcription and TATAless nature of the 
core promoter together with high GC content thus place the LTBP-3 promoter among the 
so-called broad promoters (Sandelin et al., 2007).    
4.1.2 Functional analysis of LTBP-3 promoter in cultured cells 
Before the functional promoter analysis, several cell lines were screened for their LTBP-3 
mRNA expression. MG-63 osteosarcoma cells and CCL-137 embryonic lung fibroblasts 
displayed the highest mRNA expression, whereas in Saos-2 osteosarcoma cells, the 
expression was almost undetectable. The functionality of the promoter construct 
containing the 3.0 kb upstream fragment of LTBP-3 gene cloned into the firefly luciferase 
reporter vector was tested in the same cell lines. The transcriptional activity of the 3.0 kb 
promoter construct was highest in MG-63 and CCL-137 cells, which was in accordance 
with Northern analysis and thus indicated that the cloned sequence was regulated as the 
endogenous gene. 
Next, a panel of 5’-shortened promoter fragments was produced and cloned into the 
luciferase reporter vector. Promoter constructs were then transfected into MG-63 cells, 
which were selected for further analysis of LTBP-3 gene regulation. The subsequent 
monitoring of the promoter activity revealed that the region -842-(-477) is critical for the 
basal promoter activity (Fig.3 in I). Accordingly, this region contains binding sites for Sp1 
transcription factors, which were conserved between human and mouse sequences. A total 
loss of promoter activity was observed after deleting the sequence upstream of -262. A 
region -477-(-262) contains most of the identified transcription initiation sites and is very 
similar to the mouse sequence, thus emphasizing its importance in the regulation of 
transcription in both species.   
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4.1.3 Smad and Erk pathways mediate the TGF-β induced transcriptional 
activation of LTBP-3 promoter 
Since LTBP-3 maintains the normal development of the bone (Dabovic et al., 2002) and 
knowing that bone is a rich source of growth factors, it was decided to analyze whether 
these factors could regulate LTBP-3 transcription. TGF-β, BMPs and FGFs are cytokines 
inducing osteoblast differentiation and were included in this analysis. EGF was included 
on the basis that there is abundant evidence to indicate that EGFR ligands stimulate 
osteoblast proliferation and inhibit their differentiation (Schneider et al., 2009). It was 
observed that in MG-63 osteosarcoma cells TGF-β1 stimulated LTBP-3 promoter activity 
4-5 fold, whereas other tested growth factors were ineffective. TGF-β2 and -3 affected 
transcriptional activity in a similar manner. Previously, LTBP-3 was found to exert a role 
during early phases of osteogenic differentiation by regulating TGF-β activity (Koli et al., 
2008). Koli et al. observed that during the differentiation process TGF-β3 mRNA levels 
dramatically decreased, which was associated with concomitant reduction in LTBP-3 
mRNA levels (Koli et al., 2008). Thus, it is possible that TGF-β3 stimulates LTBP-3 
expression in undifferentiated cells and that during the osteoblast differentiation TGF-β3 
downregulation leads to decreased LTBP-3 levels and consequently to decreased active 
TGF-β, which is fundamental for bone matrix mineralization. Current study did not reveal 
any significant stimulatory effect elicited by vitamin D3 metabolites or any other steroid 
hormones on LTBP-3 promoter. 1α,25(OH)2D3, 25(OH)D3, α-retinoic acid, 
dexamethasone, β-estradiol and tamoxifem were tested in this respect. 
In order to locate the TGF-β responsive region within the LTBP-3 promoter, a panel of 
promoter constructs with varying lengths were transfected into MG-63 cells and their 
transcriptional activity was monitored after TGF-β1 treatment. A significant reduction in 
TGF-β responsiveness was observed when the upstream region from -2149 was absent. 
Next the consensus Smad binding element (-2738) identified by sequence analysis was 
mutated. TGF-β responsiveness was, however, retained to some extent suggesting that 
although the SBE is important for mediating TGF-β1 stimulation, it is not on its own 
sufficient to mediate the full response. Since AP-1 interacts with Smads on several 
promoters (Wong et al., 1999; Kang et al., 2005), the AP-1 binding site was mutated at -
2251. This together with the mutation of the SBE was sufficient to decrease TGF-β 
responsiveness to the same level as observed with the promoter construct lacking the 
upstream regions from -2149. The TGF-β stimulatory effect was totally lost after deleting 
the 5’-upstream regions from the site -1313. An additional AP-1 site was located at -1382. 
The functional cooperation between Smads and AP-1 does not necessarily represent a 
direct physical interaction but may involve cooperative binding of other members of the 
transcriptional machinery by Smad and AP-1 complexes (Wong et al., 1999). 
To further identify whether the MAPK pathways trigger the transcriptional activity of 
LTBP-3 in response to TGF-β, the cells transfected with LTBP-3 promoter construct were 
stimulated with TGF-β either in the presence or absence of MAPK pathway inhibitors. 
The inhibition of JNK pathway resulted in a significant increase in the basal LTBP-3 
promoter activity, suggesting that JNK targets likely recruit factors, which can modulate 
the amplitude of transcriptional activity of LTBP-3 gene. The inhibition of the Erk 
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pathway instead remarkably decreased LTBP-3 promoter responsiveness to TGF-β. The 
p38 MAPK inhibitor did not affect LTBP-3 promoter activity in any way. 
Taken together, these results indicate that TGF-β stimulates the transcriptional 
activation of LTBP-3 gene, which is mediated through cooperative function between 
Smad3/4 and AP-1 transcription factors originating from concomitant activation of Smad 
and Erk MAPK pathways. The Smad/AP-1 interaction has also been observed with other 
promoters of ECM coding genes. Our observations together with earlier studies describing 
the TGF-β induced expression of LTBP1 (Koski et al., 1999) and LTBP2 genes (Ahmed et 
al., 1998) point to the existence of a positive regulatory loop. 
4.2 Identification of ECM binding domains of LTBP-4S (II) 
Since LTBPs determine the ECM deposition of the small latent TGF-β and have been 
implicated to affect its activation, it was decided to define the ECM targeting of LTBP-4S. 
The purpose was to elucidate molecular interactions, which could help to understand how 
latent TGF-β would be positioned in the ECM and whether these interactions play a role 
during TGF-β activation. During the course of these studies binding partners were 
identified for LTBP-4S, which are not only essential for its ECM targeting but also related 
it to novel functions in cell adhesion.  
4.2.1 LTBP-4S has several heparin binding regions 
Heparin/HSPG binding sites in ECM molecules comprise a potential target for cell 
adhesion receptors. Fibrillins, which are structurally very close to LTBPs, have several 
heparin binding sites, which support cell attachment and are involved in their ECM 
targeting (Tiedemann et al., 2001; Ritty et al., 2003). Heparin/HSPG binding sites are 
common in ECM molecules and in concert with integrin binding RGD-sequences, they 
possess the potential to affect cell signaling pathways and thus cell behavior in different 
contexts. It is noteworthy that heparin/HS are highly negatively charged molecules and 
therefore some interactions involving these molecules may represent unspecific charge 
interactions. All LTBP isoforms and FN, which is a known heparin binding molecule, 
were represented in the conditioned media from human lung fibroblast culture. In order to 
examine whether LTBP-4S has similar heparin binding characteristics as the related 
fibrillins, chromatographical analysis of conditioned media was performed by heparin 
affinity column. The observations indicated that LTBP-4S is a heparin binding protein, 
which as further examination revealed, was able to directly bind heparin. The specificity 
of the interaction was confirmed by the inhibition of the interaction by soluble heparin. 
Furthermore, these findings referred to interactions between LTBP-4S and FN, as the 
exogenously added FN increased the LTBP-4S/heparin interaction to some extent in the 
binding assays. LTBP-4 binding to heparin occurred also in the absence of FN. In another 
study, it was revealed that HSPGs mediated indirect interaction between LTBP-1 and FN 
(Chen et al., 2007), which was critical for the ECM association of LTBP-1. These 
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observations emphasized the significance of heparin/HSPG binding sites for the ECM 
accumulation of LTBP-4S, but in contrast to LTBP-1, our findings referred to direct 
interaction between LTBP-4S and FN (see 4.2.3). 
In order to locate the heparin binding regions of LTBP-4S, two set of expression 
constructs were designed (Fig. 6, section 3.2): Ig-tagged constructs spanning the entire 
sequence of the full length protein and the N-terminally truncated constructs lacking that 
part of the sequence, which was previously shown to associate with the ECM of 
fibroblasts (Koli et al., 2005). Binding assay with Ig-tagged fragments revealed that 
LTBP-4S has a strong heparin binding site in its N-terminal domain in addition to weaker 
binding sites in the central and the C-terminal parts of the molecule (Fig. 7). However, 
despite the deletion of the N-terminal domain the heparin binding properties of LTBP-4S 
were not substantially changed (Fig. 2C in II). Thus, it is likely that in the full length 
protein, several heparin binding sites act together and require the correct conformation of 
the protein to increase the avidity of the interaction. 
4.2.2 The C-terminal domain of LTBP-4 supports fibroblast adhesion and 
partially employs HSPGs 
After the characterization of the heparin binding regions of LTBP-4S it was decided to 
study, whether these regions could mediate cell adhesion, as had been previously 
demonstrated for the other members of the LTBP/fibrillin family. The findings indicated 
that adhesive properties were not restricted to LTBP-2 and fibrillins, as LTBP-4S was able 
to support fibroblast adhesion in a concentration-dependent manner. Cell adhesion site 
was confined to the C-terminal domain of LTBP-4S, which according to these 
experiments included weak heparin/HSPG binding site(s). Consistently, heparin inhibited 
cell adhesion to the C-terminal domain. Compared to the other LTBPs, the C-terminal 
domain of LTBP-4 is especially proline-rich. The proline-rich region preceeding the 
hybrid domain of LTBP-2 can support fibroblast as well as melanoma cell adhesion 
(Hyytiäinen and Keski-Oja, 2003; Vehviläinen et al., 2003). However, the full-length 
LTBP-2 does not support fibroblast adhesion. Furthermore, in association with FN, the 
domain mediating cell adhesion is known to be antiadhesive to fibroblasts (Hyytiäinen and 
Keski-Oja, 2003). It thus appears that contacts with other ECM constituents have 
remarkable effects on properties of LTBPs, since these interactions may contribute to the 
molecular changes further revealing domains, which would otherwise be inaccessible. 
Melanoma cell adhesion to LTBP-2 involves both integrins and HSPGs (Vehviläinen et 
al., 2003). Observations made in the present study suggested that HSPGs are at least 
partially mediating fibroblast adhesion to LTBP-4S, as the enzymatic disruption of 
glycosaminoglycan side chains decreased adhesion by 30% (Fig.3E in II). Morphological 
analysis of fibroblasts indicated that they were reminiscent of other adherent cells on 
heparin-binding proteins: the cell spreading was less efficient and the amount of stress 
fibers was reduced. 
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4.2.3 The N-terminal FN binding sites are critical for the ECM targeting of 
LTBP-4S 
Based on previous studies it was evident that the N-terminal domain of LTBPs has a 
special role in the ECM deposition of LTBPs (Taipale et al., 1994; Olofsson et al., 1995; 
Koli et al., 2005). Furthermore, it was observed that in cell culture LTBP-4S initially 
colocalized with FN, but later on it associated with FN-independent structures (Koli et al., 
2005). Since observations made in this study pointed to an interaction between LTBP-4S 
and FN, it was next analyzed in more detail, whether LTBP-4S could bind directly to FN 
and whether this interaction would be important for the ECM sequestration of LTBP-4. 
Binding assays indicated dose-dependent binding of plasma FN to LTBP-4S. To further 
narrow down the FN binding site, binding assays were conducted with LTBP-4 fragments. 
These experiments indicated that FN binding of LTBP-4S occurs through its N-terminal 
domain (aa 1-397) (Fig. 7.) and that there are more than one binding site. Interestingly, the 
deletion of the short N-terminal region corresponding to exon 1 (aa 1-77) was sufficient to 
decrease LTBP-4S binding to FN. However, an additional deletion (aa 1-397) was 
required to finally prevent LTBP-4S binding to FN (Fig. 4D in II). It was also found that 
heparin decreased the binding of the N-terminal domain of LTBP-4S to FN, thus 
indicating that the heparin and FN binding sites are likely near to each other. 
 
Figure 7. The FN and heparin binding domains of LTBP-4S. ++ denotes strong interaction, + 
weak interaction and – no interaction. Modified from Fig. 2. in II. 
In cultured mouse fibroblasts, LTBP-4S initially colocalized with FN, which was 
consistent with earlier observations from human fibroblast studies. LTBPs-1 and -4 have a 
fibrillin binding site in their C-terminal domain. It has been observed previously that in 
human tendon, perichondrium, cartilage and in blood vessels, LTBP-1 significantly 
codistributes with fibrillin-1 and as confirmed by immunolocalization analyses, it is a 
microfibril-associated protein (Isogai et al., 2003). Current study was conducted to analyze 
LTBP-4 colocalization with fibrillin-1 in parallel to FN colocalization in mouse fibroblast 
cultures. After 3 days of cell culture maturation, when LTBP-4 started to appear into the 
ECM and was colocalized with FN, fibrillin-1 was not yet present in the ECM. At 5 days, 
however, LTBP-4S was localized to similar fibrillar structures as fibrillin-1, suggesting 
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that LTBP-4S/fibrillin-1 interaction is potentially critical for the spatial distribution of 
LTBP-4 within a more complex milieu. The potential interaction between LTBP-4 and 
fibrillin-1 was not examined, but others have subsequently demonstrated that fibrillin-1 
null dermal fibroblasts do not incorporate LTBP-4 into their matrices (Ono et al., 2009). 
Furthermore, in the dermis and perichondrium of wild type mice, LTBP-4S was localized 
in fibrillar patterns reminiscent of fibrillin-1 fibrils, whereas in the fibrillin-1 null tissues, 
the number of LTBP-4 positive fibrils was remarkably reduced. LTBPs-1 and -2 are also 
dependent on fibrillin-1 for their association with ECM structures (Ono et al., 2009; 
Vehviläinen et al., 2009). 
 Since the observations of the present study suggested that LTBP-4/FN interaction 
would be particularly important during the early phases of ECM deposition, the 
association of LTBP-4S with the mouse fibroblast ECM devoid of FN was examined next. 
LTBP-4S was not assembled into the ECM of FN null fibroblasts, although it was secreted 
into the culture medium (Fig. 6 in II). The assembly process was rescued by exogenous 
plasma FN indicating that the formation of FN fibrils is a prerequisite for the ECM 
targeting of LTBP-4S. Previous studies have indicated that the FN fibril network serves as 
an initial scaffold preceding the ECM accumulation of LTBP-1 (Dallas et al., 2005). In 
disagreement with these findings, Ono et al. reported that fibrillin-1 null dermal 
fibroblasts did not incorporate LTBPs-1 and -4 into their matrix although FN fibrils were 
present (Ono et al., 2009). The mouse embryonic lung fibroblasts used in the present study 
produced much more intense FN fibrillar network than dermal fibroblasts, and thus cell-
specific differences may partially account for conflicting results. FN acts as an initial 
organizer of the ECM and the assemblies of many ECM proteins, including fibrillin-1 
(Kinsey et al., 2008), depend on the formation of the FN fibrillar network. Current 
experiments provided evidence that the N-terminal domain, which includes at least two 
FN binding sites, is indispensable for the ECM targeting of LTBP-4S. The known 
fibrillin-1 binding site, however, resides in the C-terminal end of the protein. Thus, it is 
believed that the N-terminal domain of LTBP-4S directs the initial ECM association of 
LTBP-4 and that the other interactions predominate in a more mature ECM.  It is likely 
that the early interactions with the ECM and particularly the binding to FN changes the 
conformation of LTBP-4S so that other ECM binding regions become accessible. In 
fibrillin-1 null tissues, LTBP-4 positive fibrils were still present, but compared to wild 
type tissues, their amount was reduced (Ono et al., 2009). This further confirms that there 
are also other interactions which determine the localization of LTBP-4 in tissues. Based on 
the present observations, it seems likely that interactions with FN and HSPGs are 
important. 
4.2.4 Disturbed LTBP-mediated sequestration of TGF-β exposes growth 
factor to increased activation 
The sequestration of latent TGF-β into the ECM ensures the availability of the growth 
factor, when it is urgently needed for cellular demands. Furthermore, interactions with the 
ECM control the activity of the growth factor, as they may prevent or promote its 
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availability to activating mechanisms. Therefore, the disturbed ECM targeting of LTBPs is 
likely to contribute to unbalanced TGF-β signaling further advancing effects which are 
unfavourable to tissues. It was decided to examine, how the defective ECM targeting of 
LTBP-4 (and LTBP-1) affects TGF-β activation in mouse fibroblasts cultures. It was 
observed that the lack of FN fibrillar network led to increased amounts of active TGF-β in 
the conditioned media of mouse fibroblasts. At the same time, the total amount of TGF-β 
was increased. These results are consistent with in vivo findings, which have indicated that 
the disruption of fibrillin-1 microfibrils in mice leads to elevated TGF-β activity, further 
contributing to the pathogenesis of Marfan syndrome (Neptune et al., 2003; Ng et al., 
2004). Microfibrils are thought to harbour LLCs after their relocation from FN fibrils 
(Ramirez and Rifkin, 2009). 
4.3 Functional characterization of N-terminal variants of LTBP-4 
(III) 
Common among LTBPs are multiple splice variants, which either lack some of the EGF-
like repeats or have different N-terminal ends. In addition, one of the splice variants of 
LTBP-4 lacks the 3rd 8-Cys repeat and consequently is unable to bind TGF-β (Koli et al., 
2001). The functional reason for this extensive structural variation has remained largely 
unclear. The purpose of our studies was to elucidate the functional differences or 
similarities between the N-terminally distinct forms of LTBP-4 (Fig. 8). These studies 
provided information about the organization of LTBP-4 regulatory regions, which forms a 
basis to further understand the prevailing conditions in tissues regulating the expression of 
LTBP-4 variants. Furthermore, the present studies indicated that there are significant 
differences in the expression, secretion, processing and ECM targeting between LTBP-4S 
and -4L. Thus, these findings help to unravel the complexity of TGF-β targeting and 
activation. 
 
 
Figure 8. The N-terminal variants of LTBP-4. Modified from Fig. 1 in III. 
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4.3.1 Tissue distribution of LTBP-4 variants refers to specific roles in human 
tissues 
In a previous study a high mRNA expression of LTBP-4 was detected in the heart, uterus, 
small intestine and in the aorta (Saharinen et al., 1998). To gain insight into differences in 
the expression of LTBP-4 N-terminal variants cDNA probes were designed which were 
specific for the N-terminal ends of LTBP-4S and -4L.  The hybridization-ready Northern 
blots representing 12 human tissues were used in the analysis. According to the results the 
heart and skeletal muscle express LTBP-4S and -4L at high levels. In addition, significant 
expression of LTBP-4S was found in the small intestine and in the lung, whereas LTBP-
4L was highly abundant in the liver (Fig.1 in III). Overall, the expression patterns of the 
N-terminal variants of LTBP-4 in the examined tissues were opposite to each other. 
Therefore, it appears that LTBP-4S and -4L have specific functions in tissues. The same 
conclusion can be drawn from a study describing the phenotype of Ltbp4 hypomorphic 
mice (Sterner-Kock et al., 2002). The disruption of Ltbp4S in mice leads to the 
development of colorectal cancer and lung emphysema. In humans, the reported mutations 
of LTBP4 gene prevent the expression of both N-terminal variants, which causes a severe 
syndrome affecting the development of multiple organs (Urban et al., 2009). The results of 
the present study pinpointing the distribution of LTBP-4S and -4L in human tissues were 
in agreement with the observed phenotypes. Some phenotypic differences between LTBP-
4 deficient mice and humans with LTBP4 mutations may arise from species-specific 
functions or from the longer time of development of the disease like colorectal cancer. 
LTBP-4 deficient patients die already in infancy or early childhood. LTBP4 mutations 
contributed to the increased activation of TGF-β and defective elastic fibers in the affected 
tissues. 
4.3.2 Two independent promoters control the expression of LTBP-4S and -
4L 
The expression pattern of the N-terminal variants of LTBP-4 suggested that at the 
transcriptional level, the expression could be directed by the use of alternative promoters. 
A similar mechanism of transcriptional control also exists in the case of other ECM 
proteins including LTBP-1 (Koski et al., 1999). To examine if the same regulatory 
mechanism applies to LTBP-4S and -4L, first the transcription initiation sites were 
identified by amplifying the 5’-cDNA ends. The sequence analysis of the amplification 
products representing LTBP-4S revealed several potential sites for the initiation of 
transcription. These findings indicated that the 5’-upstream region of LTBP-4 possesses 
the potential to independently regulate the expression of the shorter variant. To 
consolidate this view, it was decided to examine whether the 5’-upstream regions of 
LTBP-4S and -4L contained regulatory elements, which could refer to the transcriptional 
control of gene expression. As was expected based on the presence of multiple 
transcription initiation sites, no common elements, like a TATA-box, for binding the basal 
transcriptional machinery were found. Furthermore, sequence analysis indicated that both 
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regions were highly GC-rich. Similar characteristics were previously found to apply to the 
LTBP-3 promoter (I). Our analysis did reveal, however, multiple XCPE sites, which have 
been identified on TATAless promoters driving activator-, mediator and TBP-dependent, 
but TFIID-independent transcription (Tokusumi et al., 2007). In contrast, no multiple start 
site downstream elements (MED-1) (Ince and Scotto, 1995), which were present on 
LTBP-3 promoter (I), were found. 
Further confirmation to the regulatory functions of the 5’-upstream regions of LTBP-
4S and -4L was attained by identifying several potential sequence-specific transcription 
factor binding sites (Fig. 9). Multiple binding sites for the GATA family of transcription 
factors together with Sp1 binding sites were identified on both 5’-upstream regions. 
GATA transcription factors are important regulators of development and differentiation. 
Although they have been primarily considered as transcriptional regulators of 
hematopoietic differentiation (GATA1-3) and heart development (GATA4-6), it is now 
accepted that their functions are not limited to only these systems. There is increasing 
evidence to indicate that they are required in a number of tissues to control cell-specific 
expression. For example, GATA2-3 are also expressed in the brain (Nardelli et al., 1999), 
whereas GATA4-6 are found in tissues of mesodermal and endodermal origin, like heart, 
lung, liver and gut (Molkentin, 2000). GATA6 appears to mediate the profibrotic effects 
of TGF-β, leading to the formation of fibroblastic foci in the lungs of idiopathic 
pulmonary fibrosis patients (Leppäranta et al., 2010). Because in many GATA-expressing 
organs there is a significant expression of LTBP-4 as well, GATA factors can be 
considered as candidate regulators of LTBP-4 transcription. The presence of several Sp1 
binding sites is in line with the TATAless nature of the 5’-upstream regions of LTBP-4 
variants, as Sp1 has been found to recruit TBP onto promoters lacking the TATA box 
(Carninci et al., 2006). Most of the other identified transcription factor binding sites were 
equally distributed along the 5’-upstream regions of both LTBP-4 variants. However, 
there were clear differences in potential binding sites of non-ubiquitous transcription 
factors, which likely account for expressional differences in tissues. For example, the 
members of the bZIP transcription factors cAMP response element binding protein 
(CREB) and CCAAT/enhancer binding protein (C/EBP) most probably associate with the 
regulatory region of LTBP-4L. Instead, Smad binding sites were only identified upstream 
from the translation initiation site of LTBP-4S. C/EBP binding sites have been found in 
many regulatory regions of liver-specific genes (Cereghini, 1996). This is in accordance 
with the observed expression of LTBP-4L in the liver. The characteristic features of 
LTBP-3, -4S and -4L promoters are summarized in Table VI. 
 
Figure 9. Schematic representation of the genomic organization of LTBP-4 N-terminal region 
and the location of potential transcription factor binding sites. Adopted from III. 
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Table VI. Characteristics of an LTBP promoter 
Characteristics of an LTBP promoter 
Promoter TSS Sequence 
characteristics 
Core 
promoter 
elements 
Putative 
TF binding 
sites 
Other 
LTBP-3 (3.0 kb) several TATAless, 
GC-rich 
MED-1 
(two) 
Sp1, AP-1, 
Runx, SBE, 
c-Ets, 
MZF-1, 
GATA 
TGF-β 
stimulates 
transcriptional 
activation 
through Smad 
and Erk 
pathways 
LTBP-4S (1.0 kb) several TATAless, 
GC-rich 
XCPE 
(multiple) 
GATA, 
Sp1, SBE 
 
LTBP-4L (1.0 kb) not 
determined 
TATAless, 
GC-rich 
XCPE 
(multiple) 
GATA, 
Sp1, 
CREB, 
C/EBP 
 
 
Functional promoter analysis ultimately proved that the expression of the N-terminal 
variants of LTBP-4 is under the control of two independent promoters. The usage of 
multiple promoter regions enables the expression of alternative protein products to meet 
the cellular needs in different tissues and conditions. The regulatory potential of the ~1kb 
region upstream from the translation initiation site was examined, which however may 
represent only a part of the regions responsible for the transcriptional control of LTBP-4 
expression. The current belief is that significant regulatory elements, like enhancers, may 
exist even several kilobases from the translation initiation site (Heintzman and Ren, 2009). 
The lack of these potential control elements of transcription may account for the rather 
low promoter activities observed in these experiments. Functional analysis was performed 
in CCL-137, A549 and HepG2 cells, which were selected based on LTBP-4 expression in 
tissues from which these cells were derived. The transcriptional activity of the LTBP-4L 
promoter was consistently higher than the activity of the 5’-flanking region of the shorter 
variant. In A549 cells, the transcriptional activity of the LTBP-4S was 6- and of LTBP-4L 
18-fold compared to the the empty pGL3-Enhancer control vector, indicating that both 
upstream regions act as functional promoters (Fig. 4 in III). Furthermore, in the reverse 
orientation, both promoter activities were lost, evidence for the orientation-dependent 
function. 
4.3.3 LTBP-4S and -4L have significant differences in their secretion, 
processing and ECM targeting in cultured cells 
After the identification of the expressional and regulatory differences between LTBP-4S 
and -4L, it was decided to examine, whether their ECM targeting would differ. Knowing 
that LTBP-4S targets TGF-β into the ECM, and assuming that the same also applies to 
LTBP-4L, these potential differences in the ECM deposition were considered critical for 
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the regulation of TGF-β activity. To gain an insight into ECM binding properties of 
LTBP-4L, cell clones were established with stable LTBP-4L expression. The behavior of 
LTBP-4S in MEF cultures was described previously (II). The results indicated that the 
secretion of LTBP-4L and its association with ECM structures was very different from 
LTBP-4S. Initially, LTBP-4L was secreted into the culture medium of MEFs and CHO 
cells, but during culturing, the cells eventually lost this ability (Fig. 5A in III). When the 
cells were examined by immunofluorescence analysis, it was found that LTBP-4L was 
retained inside the cells (Fig. 5B in III). The gradual loss of LTBP-4L expression became 
apparent during extended culturing. Since transiently transfected cells efficiently secreted 
both LTBP-4 variants and even deposited it into their ECM at occasional sites, it is 
possible that the secretory system in stable cell clones had become overloaded. It is also 
possible that the production of LTBP-4L was not favourable to the cells in question, which 
led to the overpopulation of cultures with cells without LTBP-4L expression. In addition 
to MEFs, similar results were obtained using CHO, CCL-137 and HepG2 cells. 
To enable the further characterization of LTBP-4L and particularly to allow its 
analysis under nonreducing conditions, LTBP-4 constructs were designed in which the 
endogenous signal sequence was replaced by the signal sequence of the FLAG-expression 
vector. Since the FLAG-tag was N-terminal it was possible to make a distinction between 
LTBP-4S and -4L, in contrast to anti-LTBP-4 antibodies, which recognize the C-terminal 
domain of the protein. The secretion of LTBP-4S and -4L from CHO cells was then 
analyzed by immunoprecipitation using anti-FLAG affinity gel followed by 
immunoblotting using another anti-FLAG antibody. Both FLAG-tagged LTBP-4 variants 
were efficiently secreted. A significant difference was observed in their secretion: LTBP-
4S was mainly detected as a ~230 kDa protein band representing the free form of the 
protein, whereas the longer variant was not only detected as a free form but also as high 
molecular weight band(s) (>250 kDa), which were similar in size to the LTBP/TGF-β 
complex (Fig. 6A in III). Furthermore, under reducing conditions, the high molecular 
weight bands disappeared suggesting that these complexes had been formed by disulfide 
bonding. It was reported previously that LTBP-4S is able form a complex with TGF-β1 
(Saharinen et al., 1998), which was also detected after longer exposure times. To verify 
that LTBP-4L containing complexes have TGF-β1 as well, immunoprecipitation with anti-
FLAG-affinity gel was followed by immunoblotting using anti-LAP-β1 and anti-FLAG 
antibodies. Both antibodies detected high molecular weight bands of similar size, 
indicating that LTBP-4L is a TGF-β1 binding protein (Fig 6C in III). The amount of 
LTBP-4L containing complexes increased significantly after LAP-β1 cotransfection. The 
ability of LTBP-4L to form complexes with TGF-β1 appears to be comparable to LTBPs-
1 and -3, whereas LTBP-4S seems to bind TGF-β1 less efficiently. It has been 
demonstrated that in vitro LTBP-4S does not bind TGF-β2 or –β3 (Saharinen and Keski-
Oja, 2000). However, it was recently observed that the disruption of Tgf-β2 in Ltbp4S null 
mice could rescue the terminal air-sac septation in the lungs (Dabovic et al., 2009). It was 
speculated that the elimination of Tgf-β2 could potentially normalize the levels of all TGF-
β isoforms, which are unbalanced in Ltbp4S -/- lung fibroblasts (Koli et al., 2004). 
Another explanation could be that in vivo the TGF-β binding characteristics of LTBP-4S 
differ from that observed in vitro. Whether LTBP-4L forms complexes with other TGF-β 
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isoforms than TGF-β1 is unclear at present. The difference in the complex formation with 
TGF-β1 between LTBP-4S and -4L is particularly interesting, since they differ only in 
their N-terminal domains. Perhaps the N-terminal domain of LTBP-4L has such a 
dramatic effect on molecular folding that the interaction with TGF-β becomes more 
favourable. The characteristic features of LTBP-4S and -4L identified in the present study 
are summarized in Table VII. 
 
Table VII. Summary of the characteristics of LTBP-4S and -4L 
Expression and structural characteristics of the N-terminal variants of LTBP-4 
N-
terminal 
variant 
Highest  
mRNA 
expres-
sion 
Interacting 
ECM 
components 
Site of 
interaction 
Functional 
role of the 
interaction 
Complex 
formation 
with TGF-
β1 
Secretion 
(transfected 
CHO cells) 
LTBP-4S heart, 
skeletal 
muscle, 
small 
intestine, 
lung 
FN 
 
Heparin 
 
 
 
 
 
 
 
 
Fibrillin-1 
N-terminal 
domain 
Strong N-
terminal 
binding site 
Weak 
binding 
sites in the 
central and 
C-terminal 
domain 
C-terminal 
domain  
ECM 
targeting 
ECM 
targeting 
 
Cell 
adhesion 
 
 
 
 
ECM 
targeting 
yes Mainly 
secreted as 
a free form 
LTBP-4L heart, 
skeletal 
muscle, 
liver 
   yes Secreted in 
a complex 
with TGF-β, 
but also as a 
free form 
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5 Perspective 
Despite the undisputable role of LTBPs during the ECM accumulation and activation of 
TGF-β, the molecular details underlying these processes have remained largely 
unexplained. On the basis of several studies, it appears that the mechanisms regulating 
TGF-β are highly complex and context dependent. This study has provided insights into 
the ECM localization of LTBP-4 and revealed interactions which not only determine the 
matrix requirements for LTBP-4 binding, but also ultimately affect the activation of TGF-
β. The observation that LTBP-4S has a FN binding site in its very N-terminal domain was 
particularly interesting, as this region is specific for the shorter LTBP-4 variant. Therefore, 
it would be of interest to analyse whether LTBP-4L binds FN via its N-terminal domain 
and if this has importance for the ECM binding of LTBP-4L. This study also identified 
heparin binding sites in LTBP-4S, of which the C-terminal site was likely involved in cell 
adhesion. Future studies should focus on investigating the potential functional role of the 
other heparin binding sites. As these studies already suggested, they may have importance 
during the ECM targeting of LTBP-4S. Therefore, a more detailed analysis with heparin 
binding LTBP-4 fragments could give a more comprehensive view of the assembly 
process. These studies revealed a significant difference in the ratio between the secreted 
free and complexed forms of LTBP-4S and -4L. Thus, the contribution of the N-terminal 
variants of LTBP-4 to the activation of TGF-β is likely different and worth studying 
further. A future challenge would be to do molecular modeling to gain insights into, why 
these two forms of LTBP-4 though having a similar TGF-β binding domain, differ in their 
TGF-β binding characteristics. Additional studies are also required to clarify the binding 
of different TGF-β isoforms with LTBP-4 variants. The in vitro data indicates that LTBP-
4S binds only TGF-β1, but on the basis of recent findings, in vivo conditions may favor 
interactions with other isoforms as well (Dabovic et al., 2009). 
The characterization of the promoter regions of LTBP-3 and -4 genes described in this 
study have laid the foundation for understanding the functions and expression of LTBPs 
under normal and pathological conditions. A reduced expression of LTBPs has been 
observed in cancers: the downregulation of LTBP-3 expression was recently observed in 
malignant mesothelioma (Vehviläinen, 2010), whereas reduced LTBP-4 expression was 
found in human breast tumors (Mauel et al., 2007). Thus, the promoter studies could be 
extended to cell lines derived from these tumors to gain insights into the molecular 
background of these diseases. Since LTBP-4 is involved in elastogenesis, understanding 
the regulatory mechanisms of this gene may also have importance in connective tissue 
disorders associated with defective elastic fibers. Furthermore, the mechanism of 
transcriptional downregulation of LTBP-3 during osteogenic differentiation of 
mesenchymal stem cells could be studied using the promoter constructs created in this 
study. 
To conclude, the main findings described here give insights into the transcriptional 
control of LTBP genes. Information on control elements, like core promoter elements and 
transcription factor binding sites within a promoter region, is critical for understanding the 
functions of LTBP genes in different tissues. This, together with information on the ECM 
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binding properties of LTBPs, is essential for gaining a comprehensive view on 
mechanisms affecting the activation of TGF-β in different tissues. 
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